INTELLECTUAL PROPERTY OFFICE
BRUNEI DARUSSALAM

31 January 2022

NO. 001/2022

PATENT JOURNAL

Brunei Darussalam Intellectual Property Office (BruIPO)
The Law Building, Ground Floor
Jalan Raja Isteri Pengiran Anak Saleha
Bandar Seri Begawan BA1910
Negara Brunei Darussalam
Tel: +673 2244873/4/5/6 Ext 102
Email: enquiries@bruipo.gov.bn

CONTENTS

******

General Information

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)
Attorney General's Chamber
The Law Building,
Jalan Raja Isteri Pengiran Anak Hajah Saleha,
Bandar Seri Begawan BA1910
Brunei Darussalam
Tel: +673 2225919

Opening Hours

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	:	8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	:	8.00am to 11.00am
Friday and Sunday	:	CLOSED

Submission of Applications

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).

2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

Enquiries

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B$10.00 per copy.

2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is http://www.bruipo.gov.bn.

3. All Patent-related enquiries via email can be submitted to enquiries@bruipo.gov.bn

******

Patents Legislation

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.

2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541

3. The soft copies of the legislation can be obtained from www.bruipo.gov.bn

Forms and Fees

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.

2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

Restrictions on Applications Abroad by Residents of Brunei Darussalam

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.

2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

Transitional Applications

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:

- Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
- Lodgement of Patent Form PF46;
- Certified true copy of the grant of patent in the relevant country;
- Prescribed fee of B$250.00; and
- Any other supporting documents that the Registrar deems necessary.

2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.

3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of $6.50 per hour.

******

‘INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS

'INID' is an acronym for '**I**nternationally agreed **N**umbers for the **I**dentification of **D**ata'

(10) Document identification
- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data
- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data
- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public
- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information
- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)
- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document

(70) Name(s) of nominated person
(71) Name(s) of applicant(s).
(72) Name(s) of inventor(s) if known to be such.
(74) Name(s) of attorney(s) or agent(s).
(75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention
(86) PCT Application Number.
(87) PCT Publication Number.

NOTE
(1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
(2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.

******

PRACTICE NOTE 2012/01

PATENT RENEWALS

- **RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER**

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

   (a) PF20;
   (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
   (c) evidence of the original patent not having been revoked, and
   (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. PF20

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. PF46

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. PF21

Extension fees will become payable for renewals as of 1 January 2013.

5. Certification of original patent

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a

statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

AMENDMENT OF RULE 92 OF S 19/2012

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

"(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.".

AMENDMENTS AND CORRECTIONS

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**

1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.

2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**

1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.

2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.

Example 1: Page 10 of 19 sheets (Specification) is amended



Example 2: Page 10 of 19 sheets (Specification) is amended



Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

Example 4: Page 10 of 19 sheets (Specification) is amended



- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

REGISTRATION UNDER SECTION 115

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA

******

FIRST SCHEDULE

FEES PAYABLE

Matter	Fee	Corresponding Form(s)
1. On filing a request for the grant of a patent	$160.00	1
2. On reference under section 20(1) or 48(1)	$450.00	2
3. On filing a counter-statement in each of the following cases –	$40.00	3
(*a*) Opposing the making of an order under section 20 or 48		
(*b*) Opposing a request under section 22		
(*c*) In respect of a reference under section 23(5)		
(*d*) Opposing an application under section 24		
(*e*) In answer to a notice of opposition under section 38		
(*f*) In answer to a notice of opposition under section 41		
(*g*) In respect of a reference under section 49(5)		
(*h*) In respect of an application under section 55(3)		
(*i*) In answer to a notice of opposition under section 5 6(7)		
(*j*) In respect of a reference under section 65(3)		
(*k*) On contesting an application under section 76 for declaration of non- infringement		
(*l*) On contesting an application under section 77 for revocation of a patent		
(*m*) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	$50.00	4
5. On request for directions under section 22	$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	$1750.00	11
12. On filing a request for a search and examination report	$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(*a*) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	$200.00	
(*b*) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	$200.00 plus $20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20

(a) for each year in respect of the 5th. 6th or 7th year of the patent	$160.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	$270.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	$350.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	$450.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	$550.00	
(f) for the 20th year of the patent	$650.00	
(g) for each year after the 20th year of the patent	$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(*a*) not exceeding one month	$50.00	
(*b*) each succeeding month (but not exceeding 6 months)	$100.00	
21. On application to amend specification after grant	$100.00	22
22. On notice of opposition to amendment of specification after grant	$480.00	23
23. On application for the restoration of a patent	$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	$300.00	25
25. On filing an offer to surrender a patent	$70.00	26
26. On notice of opposition to offer to surrender a patent	$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –		
(*a*) each alteration or correction of name	$12.00	28

(*b*) each alteration or correction of address (not being an address for service)		
29. On filing a request, in respect of each patent or application for a patent, for –	$12.00	28
(*a*) each alteration or correction of address for service		
(*b*) each correction of an error in the register or any connected document		
(*c*) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application		
30. On request for the furnishing of or access to miscellaneous information –		30
(*a*) fee for inspecting each file or document relating to a patent or patent application	$6.50	
(*b*) fee for furnishing each file or document	$6.00	
(*c*) fee for photocopying each page or part thereof of any other document by the staff of the Registry	$0.30	
(*d*) where the document is placed in the public search room –		
(i) fee for self-service photocopying of each page or part of the document using a stored-value card	$0.15	
(ii) fee for photocopying of each page or part thereof by the staff of the Registry	$0.30	
31. On request for certificate of the Registrar –		31
(*a*) by impressed stamp -		
(i) for the first 20 sheets	$18.00	
(ii) for each additional sheet thereafter	$0.30	
(*b*) sealed and attached to the documents -		
(i) for the first 20 sheets	$30.00	

(ii) for each additional sheet thereafter	$0.30	
(*c*) in respect of a priority document under rule 17.1(*b*) of the Regulations under the Patent Cooperation Treaty	$50.00	
(*d*) in respect of a certified copy of the international application for a patent under rule 124	$28.00	
32. On application for entry of order of court in the register	$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	$70.00	33
34. On application for settlement of terms of licence of right	$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	$90.00	36
37. On reference to the Registrar of a dispute as to infringement	$280.00	37
38. On application for declaration of non- infringement	$280.00	38
39. On application under section 77 for the revocation of a patent	$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	$160.00	42
42. On payment of prescribed fee and request for publication of translation	$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	$100.00	48
48. On request for information relating to a patent or an application for a patent	$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	$200.00	50
50. On request for extension of each time or period under rule 114(6)	$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(*a*) –		51
(a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(*a*) of the Regulations under the Patent Co-operation Treaty	$250.00	-

55. On request for certificate authorising release of sample of micro-organism	$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	$275.00	
(f) for the 20th year of the patent	$325.00	
(g) for each year after the 20th year of the patent	$475.00	
59. On application to extend the term of a patent under section 36	$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	$3100.00	
(c) where the Examiner is the Hungarian Patent Office	$2680.00	
61. On filing one or more documents under section 26(7)(*c*) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	$120.00	62
63. On filing a request under rule 10(2)	$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	$2.00	
(b) for each sheet of information printed	$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	$10.00	
(b) Patents Journal B	$36.00	

******

SECOND SCHEDULE

DESCRIPTIONS OF FORMS

No.	Description of Form	Corresponding Form No.
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(*e*)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17

20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 4 1(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36

39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(*a*)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53

56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(*d*)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(*c*) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99

******

THIRD SCHEDULE

SCALE OF COSTS

PART I

BASIC COST

Item	*Matter*	*Amount*
1	Drawing and filing notice of opposition or application for revocation together with statement of case	$200.00
2	Drawing and filing a counter-statement	$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	$200.00 - $800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	$2.00 per folio
5	Preparing for all interlocutory proceedings	$25.00 - $120.00
6	Attending all interlocutory proceedings	$25.00 - $50.00
7	Preparing for hearing	$500.00 - $1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	$100.00 per hour up to a maximum of $450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	$60.00 per hour up to a maximum of $270.00 per day
10	Advocate or Solicitor fees	$120.00 per hour up to a maximum of $540.00 per day
11	Drawing bill of costs (per folio)	$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	$50.00 - $120.00

******

PART II

ADDITIONAL COSTS

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.

2. A person attending proceedings before the Registrar shall be paid –

(a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and

(b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of $250 for meals and accommodation.

3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –

(a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed $150 per day; or

(b) in any other case, an amount of not less than $100 but not more than $150 for each day on which he so attends.

******

FOURTH SCHEDULE

MICRO-ORGANISMS

Applications.

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

(a) which is not available to the public at the date of filing of the application; and

(b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

(a) a condition that –

(i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and

(ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and

(b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(*a*)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

(a) within 16 months from –
(i) the declared priority date; or
(ii) the date of filing the application where there is no declared priority date;

(b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the

date of the request; or

(c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.

(4) The giving of the information specified in sub-paragraph (2)(*a*)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

Availability of cultures.

2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –

(a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(*c*); and

(b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.

(2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –

(a) to the applicant for, or proprietor of, the patent;

(b) to the international depositary authority; and (c) to the person making the request.

(3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –

(a) not to make the culture, or any culture derived from it, available to any other person; and

(b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –

(i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,

where an application is reinstated under either of those rules, the period before it is reinstated);

(ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and

(iii) the undertaking set out in sub-paragraph (*b*) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

(a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and

(b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(*a*) has effect –

(a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or

(b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

Availability of cultures to experts.

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

(a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and

(b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is

treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(*a*) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(*a*) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;
(b) to the international depositary authority concerned;
(c) to the requester; and
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons

referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(*a*) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

New deposits.

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and

(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (*b*), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(*a*)(ii), (*b*) and (*c*), shall be made with another international depositary authority which is able to satisfy the request.

Interpretation.

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.

FIFTH SCHEDULE

REMUNERATION OF SCIENTIFIC ADVISERS

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –

   (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and

   (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of $250.

2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than $650 but not more than $2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(*b*).

3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than $650 but not more than $2,000 if he is subsequently not required to hear the proceedings with the Registrar.

******

REGISTRAR OF PATENT
BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

NEW PATENT APPLICATION

[21] **BN/N/2020/0005** **[22]** **29/01/2020**

[54] **Chemical Compositions And Methods For Remediating Hydrogen Sulfide And Other Contaminants In Hydrocarbon Based Liquids And Aqueous Solutions**

[71] **GAPS TECHNOLOGY, LLC of 501 JF Smith Avenue, Slidell, Louisiana 70460, United States of America**

[72] **1. ROE, CLIFFTON**
2. SCHWEITZER, LINDA

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/661,289 Date: 23/04/2018 Country: United States of America
No. 62/702,960 Date: 25/07/2018 Country: United States of America
No. PCT/US2018/050913 Date: 13/09/2018 Country: United States of America

[86] **PCT/US2018/064015**

[87] **WO/2019/209379**

[51] **A6IK 47/06, A610 19/00, A6IK 8/06**

[57] **A treatment process for remediating a contaminated liquid containing more than 5 ppm hydrogen sulfide and substanGil tially without formation of precipitate. includes steps of steps of adding an aqueous solution containing at least one hydroxide compound O at a collective concentration of 35 – 55 wt% to the contaminated liquid to achieve a concentration of 125-5000 ppm of the hydroxide compounds in the contaminated liquid. adding at least one organic acid and to the liquid to achieve a concentration of 0.01 – 10 ppm in the contaminated liquid. and dispersing the aqueous solution and the at least one organic acid in the contaminated liquid and allowing O the aqueous solution and the at least one organic acid to react with the contaminated liquid for a period of time until a concentration eN1 of hydrogen sulfide in the contaminated liquid is reduced to < 5 ppm.**

[21] **BN/N/2020/0025** **[22]** **31/03/2020**

[54] **Chromane Monobactam Compounds For The Treatment Of Bacterial Infections**

[71] **MERCK SHARP of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America**

[72] **1. BIFTU, TESFAYE**
2. HUANG, XIANHAI
3. LIU, WEIGUO
4. PAN, WEIDONG
5. PARK, MIN
6. PASTERNAK, ALEXANDER
7. SUN, WANYING
8. TANG, HAIFENG
9. ZANG, YI

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/566,779 Date: 02/10/2017 Country: United States of America

[86] **PCT/US2018/053039**

[87] **WO/2019/070492**

[51] **A61K 31/427, A61K 31/4439, A61K 31/433**

[57] **The present invention relates to monobactam compounds of Formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.**

(I)



---

[21] **BN/N/2020/0029** **[22]** **15/04/2020**

[54] **Heat-Not-Burn Cigarette Having Cavity Container Section**

[71] **NANTONG JIN YUAN NEW MATERIALS CO., LTD. of No.6 Shengli Road, Chongchuan District, Nantong, Jiangsu 226014, China**

[72] **1. TANG, WEI**
2. TANG, RONGCHENG
3. ZHOU, CHENGXI
4. QIN, CHANGFENG
5. LUO, LIANG

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 201710880890.3 Date: 26/09/2017 Country: China

[86] **PCT/CN2017/107271**

[87] **WO/2019/061606**

[51] **A24F 47/00**

[57] **A heat-not-burn cigarette having a cavity container section, comprising a tobacco section (1), a multi-cavity container section (6), and a lip proximity section (4) sequentially and coaxially connected, and an external wrapping material (5) for limiting the tobacco section (1), the multi-cavity container section (6), and the lip proximity section (4). The tobacco section (1) comprises a smoking material; a core material of the tobacco section (1) is wrapped by an aluminum foil composite plug wrap (2) or an oil-proof plug wrap. Due to the material of the multi-cavity container section (6), the cigarette has a good cooling property, such that a user has no sensation of burning during smoking. By providing the multi-cavity container section**

(6), the cigarette has various flavors, a thick smell, and rich smoke. By providing an aluminum foil composite plug wrap (2) on the tobacco section (1), problems of contamination and deformation of the external wrapping material (5) due to that the core material absorbs moisture from air are reduced.



图 1

---

[21] BN/N/2020/0037 **[22]** 30/04/2020

[54] **Oral Delivery Of Glp-1 Peptide Analogs**

[71] **MEDIMMUNE LIMITED of One Medimmune Way, Gaithersburg, Maryland 20878, United States of America**

[72] **1. PECHENOV, SERGEI**
2. TYAGI, PUNEET
3. SUBRAMONY, JANARDHANAN ANAND

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/579,186 Date: 31/10/2017 Country: United States of America

[86] **PCT/IB2018/058514**

[87] **WO/2019/087083**

[51] **A61P 3/10, A61K 38/26, A61K 38/22, A61K 47/10**

[57] **The present invention provides formulations for oral administration of GLP- I peptide analogs. methods of making such formulations. and methods of treatment using such formulations.**

---

[21] BN/N/2020/0042 **[22]** 02/06/2020

[54] **Panel**

[71] **BLUESCOPE STEEL LIMITED of Level 11, 120 Collins Street, Melbourne, Victoria 3000, Australia**

[72] **1. KRALIC, JOHN**
2. CELEBAN, MICHAEL
3. GALLATY, RODNEY
4. KLEES, ROBERT
5. HAMPTON, GLEN

[74] **Messrs. MIRANDAH ASIA (SINGAPORE) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 2017904751 Date: 24/11/2017 Country: Australia

[86] **PCT/IB2019/059857**

[87] **WO/2020/100120**

[51] **E04C 2/32, E04D 3/30, E04D 3/35, E04D 3/36, B32B 7/04, E04B 2/88**

[57] **A wall/roof panel (3,5) includes (a) a façade (7) that has (i) an outer surface that defines a front surface (9) of the panel CZ and (ii) a rear surface (11) and (b) a structural element (13) connected to and supporting the façade.**



Figure 26

---

[21] **BN/N/2020/0109** **[22]** **03/12/2020**

[54] **Methods Of Use Of Cd24 For The Prevention And Treatment Of Leukemia Relapse**

[71] **ONCOIMMUNE, INC. of Key West Avenue, Suite 113, Rockville, Maryland 20850, United States of America**
UNIVERSITY OF MARYLAND, BALTIMORE of Office Technology Transfer, 620 W. Lexington Street, 4th Floor, Baltimore, Maryland 21201, United States of America

[72] **1. LIU, YANG**
2. ZHENG, PAN
3. DEVENPORT, MARTIN

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/680,218 Date: 04/06/2018 Country: United States of America
No. 62/739,719 Date: 01/10/2018 Country: United States of America
No. 62/739,742 Date: 01/08/2019 Country: United States of America

[86] **PCT/US2019/035205**

[87] **WO/2020/ 236474**

[51] **C07K 14/705, C07K 16/28, C07K 16/30**

[57] **The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.**



FIG. 4

[21] **BN/N/2020/0115** **[22]** **23/12/2020**

[54] **Method Of Treating Or Ameliorating Metabolic Disorders Using Binding Proteins For Gastric Inhibitory Peptide Receptor (Gipr) In Combination With Glp-1 Agonists**

[71] **AMGEN INC.of 2855 Gazelle Court, Carlsbad, California 92010, United States of America**

[72]
1. YIE, JUNMING
2. SHI, DONGHUI
3. LLYOD, DAVID J.
4. WANG, JINGHONG
5. SIVITS, JR., GLENN N.
6. VENIANT-ELLISON, MURIELLE M.
7. KOMOROWSKI, RENEE
8. AGRAWAL, NEERAJ
9. BATES, DARREN L.
10. CLAVETTE, BRANDON C. P.
11. FOLTZ, IAN N.
12. HO, SHU-YIN
13. MURAWSKY, CHRISTOPHER
14. MIN, XIAOSHAN
15. WANG, ZHULUN

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. BN/N/2018/0062 Date: 12/02/2019 Country: Brunei Darussalam
No. 62/337,799 Date: 17/05/2016 Country: United States of America
No. 62/387,486 Date: 23/12/2015 Country: United States of America
No. 62/420,415 Date: 10/11/2016 Country: United States of America

[51] **A61K 39/39, CO7K 16/28, A61K 38/26, A61K 39/395, A61K 9/00, A61K 38/17, A61K 39/00**

[57] **Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.**

---

[21] **BN/ N/2021/0004** **[22]** **13/01/2021**

[54] **Selective Estrogen Receptor Degraders**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America**

[72] **1. COHEN, JEFFREY DANIEL**
2. SALL, DANIEL JON

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/697,100 Date: 12/07/2018 Country: United States of America
No. 62/825/172 Date: 28/03/2019 Country: United States of America

[86] **PCT/US2019/041342**

[87] **WO/2020/118437**

[51] **C07D 491/052, A61K 31/436, A61P 35/00**

[57] **Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.**



---

[21] **BN/N/2021/0024** **[22]** **10/03/2021**

[54] **Methods Of Treating Psoriasis**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America**

[72] **1. FRIEDRICH, STUART WILLIAM**
2. KLEKOTKA, PAUL ALAN
3. TUTTLE, JAY LAWRENCE

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/729,435 Date: 11/09/2018 Country: United States of America

[86] **PCT/US2019/049648**

[87] **WO/ 2020/055651**

[51] **A61K 39/395, A61P 17/06**

[57] **The present invention generally relates to the treatment of psoriasis with an antibody that binds to the p19 subunit of human IL-23, in particular dosage regimens for the treatment of the disease. X-22140 PCT -1-**

---

[21] **BN/N/2021/0025** **[22]** **17/03/2021**

[54] **Modulators Of Pnpla3 Expression**

[71] **IONIS PHARMACEUTICALS, INC. of Gewerbestrasse 16 Allschwil 4123, Switzerland**

[72] **1. FREIER, SUSAN, M.**
2. BUI, HUYNH-HOA

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/733,152 Date: 19/09/2018 Country: United States of America

[86] **PCT/US2019/051743**

[87] **WO/2020/06120**

[51] **C12N 15/113**

[57] **The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.**

---

[21] **BN/N/2021/0042** **[22]** **20/05/2021**

[54] **(54) 9-Substituted Amino Triazolo Quinazoline Derivatives As Adenosine Receptor Antagonists, Pharmaceutical Compositions And Their Use**

[71] **MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907, United States of America**

[72] **1. LARSEN, MATTHEW, A.**
2. ALI, AMJAD
3. CUMMING, JARED
4. DEMONG, DUANE
5. DENG, QIAOLIN
6. GRAHAM, THOMAS, H.
7. HENNESSY, ELISABETH
8. HOOVER, ANDREW, J.
9. LIU, PING
10. LIU, KUN
11. MANSOOR, UMAR FARUK
12. PAN, JIANPING
13. PLUMMER, CHRISTOPHER, W.
14. SATHER, AARON
15. SWAMINATHAN, UMA
16. WANG, HUIJUN
17. ZHANG, YONGLIAN

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/774,077 Date: 30/11/2018 Country: United States of America

[86] **PCT/US2019/063136**

[87] **WO/2020/131597**

[51] **A61P35/00, A61K 31/519, C07D 487/04**

[57] **In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.**



(I),

---

[21] BN/N/2021/0043 **[22]** 20/05/2021

[54] Methods Of Treating Chronic Kidney Disease With Dapagliflozin

[71] ASTRAZENECA AB of SE-151-85 Södertälje, Sweden

[72] 1. LANGKILDE, ANNA MARIA

[74] Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 61/119,711 Date: 01/12/2020 Country: United States of America
No. 63/057,139 Date: 27/07/2020 Country: United States of America
No. 63/070,869 Date: 27/08/2020 Country: United States of America
No. 63/082,524 Date: 24/09/2020 Country: United States of America
No. 63/093,961 Date: 20/10/2020 Country: United States of America
No. 63/152,445 Date: 23/02/2021 Country: United States of America
No. 63/161,629 Date: 16/03/2021 Country: United States of America

[86] PCT/EP2021/058727

[87] WO/2022/022865

[51] A61K 31/70, A61P31/12

[57] The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

---

[21] BN/N/2021/0044 **[22]** 20/05/2021

[54] **Board Of Regents Of The University Of Texas System; Case Western Reserve University And Rodeo Therapeutics Corporation**

[71] **CASE WESTERN RESERVE UNIVERSITY of 10900 Euclid Avenue Cleveland, Ohio 44106, United States of America**
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM of 210 West 7th St. Austin, Texas 78701, United States of America
RODEO THERAPEUTICS CORPORATION of 2815 EASTLAKE AVE E STE 300 SEATTLE, WASHINGTON 98102, United States of America

[72] **1. MARKOWITZ, SANFORD**
2. READY, JOSEPH
3. GWALTNEY, II, STEPHEN L.
4. ANTCZAK, MONIKA

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/770,571 Date: 21/11/2018 Country: United States of America

[86] **PCT/US2019/062686**

[87] **WO/ 2020/106998**

[51] **A61K 31/519, A61K 31/505, C07D 417/04, C07D 495/02, C07D 495/04**

[57] **Compounds and methods of modulating 15-PGDI I activity, modulating tissue prostaglandin levels, treating disease. es1 diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH C inhibitors described herein.**

---

[21] **BN/N/2021/0060** **[22]** **17/06/2021**

[54] **Compositions Comprising Streptococcus Pneumoniae Polysaccharide-Protein Conjugates And Methods Of Use Thereof**

[71] **MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907, United States of America**

[72] **1. ABEYGUNAWARDANA, CHITRANANDA**
2. CUI, YADONG ADAM
3. FERRERO, ROMULO
4. HE, JIAN

5. MUSEY, LUWY
6. PETIGARA, TANAZ
7. SKINNER, JULIE, M.

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/781,835 Date: 19/12/2018 Country: United States of America
No. 62/853,331 Date: 28/05/2019 Country: United States of America

[86] **PCT/US2019/066682**

[87] **WO/2020/131763**

[51] **A61K 39/09, A61P 31/04**

[57] **The invention is related to multivalent immunogenic compositions comprising more than one *S. pneumoniae* polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an *S. pneumoniae* serotype conjugated to a carrier protein, wherein the serotypes of *S. pneumoniae* are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against *S. pneumoniae* infection and/or pneumococcal diseases caused by *S. pneumoniae*. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.**



FIG.1

[54] **Device And Method For Oxidizing Organic Substance**

[71] **WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, Shandong 264006, China**

[72] **1. LIU, Peng**
2. SUN, Xican
3. Zhu, Faming
4. CONG, Zhenxia
5. QIAO, XIAOFEI

[74] **Messrs. PINTAS CONSULTING GROUP SDN BHD of MIA Management Services, Anggerek Desa Complex, Bandar Seri Begawan BB3780, Brunei Darussalam**

[31][32][33]
No. 201811603256.6 Date: 26/12/2018 Country: China

[86] **PCT/CN2019/086440**

[87] **WO/2020/133872**

[51] **B01J 19/24, B01J 19/00, C07C 407/00, C07C 409/08**

[57] **Disclosed are a device and method for oxidizing an organic substance, particularly a method for preparing ethylbenzene hydroperoxide by reacting ethylbenzene with an oxygen-containing gas. The device comprises a vertical bubbling reactor (1) and a horizontal bubbling reactor (11) connected to a reaction product outlet of the vertical bubbling reactor (1), wherein the horizontal bubbling reactor (11) is internally provided with a plurality of reaction compartments (21) which are arranged along the axial direction thereof, and a liquid phase channel (22) is provided between adjacent reaction compartments (21).**

---

[21] **BN/N/2021/0064** **[22]** **21/06/2021**

[54] **Stable Dispersant And Application Thereof In Preparing Copolymer Polyols**

[71] **WANHUA CHEMICAL GROUP CO., LTD of No. 17, Tianshan Rd YEDA Yantai, Shandong 264006, China**

[72] **1. LI, Fuguo**
2. LIU, Yang
3. JU, Changxun
4. LIU, Bin

5. QIN, Chengqun
6. WU, Xunkun
7. LI, Jing
8. ZHENG, Bing
9. WANG, Lunpeng

[74] Messrs. PINTAS CONSULTING GROUP SDN BHD of MIA Management Services, Anggerek Desa Complex, Bandar Seri Begawan BB3780, Brunei Darussalam

[31][32][33]
No. 201811569144.3 Date: 21/12/2018 Country: China

[86] PCT/CN2018/123934

[87] WO/2020/124645

[51] C08F 283/00, C08G 18/08, C08G 18/32, C08G 18/40

[57] Provided by the present invention are a stable dispersant and an application thereof in preparing copolymer polyols, the preparation method for the stable dispersant comprising: 1) contacting a polyol with a dianhydride compound for reaction so as to prepare an adduct; 2) performing a ring-opening addition reaction on the adduct obtained in step 1) and an epoxy compound to prepare a stable dispersant; the dianhydride compound does not contain a double bond that may copolymerize with an olefinically unsaturated monomer, while the epoxy compound contains a double bond that may copolymerize with an olefinically unsaturated monomer; the polyol is a polyester polyol and/or a polyether polyol, preferably being a polyether polyol. The stable dispersant obtained by means of the described preparation method has a multi-active site anchoring function, and is applied to the synthesis of copolymer polyols to obtain copolymer polyols having relatively uniform particle size.



---

[21] BN/N/2021/0065 [22] 21/06/2021

[54] Modified Polyether Polyol And Use Thereof In Polyurethane Foam Materials

[71] **WANHUA CHEMICAL GROUP CO., LTD of No. 17, Tianshan Rd YEDA Yantai, Shandong 264006, China**

[72] **1. LI, Fuguo**
2. LIU, Yang
3. JU, Changxun
4. Jiang, Naihua
5. LIU, Bin
6. QIN, Chengqun
7. WANG, Lunpeng

[74] **Messrs. PINTAS CONSULTING GROUP SDN BHD of MIA Management Services, Anggerek Desa Complex, Bandar Seri Begawan BB3780, Brunei Darussalam**

[86] **PCT/CN2018/123901**

[87] **WO/2020/132944**

[51] **C08G 65/332, C08G 65/331, C08G 18/66, C08G 18/65, C08G 18/63, C08G 18/48, C08G 18/32, C08F 283/06, C08F 220/44, C08F 212/08**

[57] **Provided are a modified polyether polyol and the use thereof in polyurethane foam materials. The method for preparing a modified polyether polyol comprises the following steps: 1) reacting a compound A with a polyether polyol, wherein the compound A is an anhydride and/or dicarboxylic acid compound containing a polymerizable double bond, preferably selected from one or two of maleic anhydride and itaconic anhydride, preferably maleic anhydride; and 2) reacting the product obtained in step 1) with an epoxy compound containing a polymerizable double bond in the presence of a catalyst, in order to prepare the modified polyether polyol. The modified polyether polyol obtained by means of the preparation method has more active sites, uses the polymerizable double bond for blocking, is used as a dispersion stabilizer for the synthesis of copolymer polyols, and has the characteristics of a better dispersion stability, filterability and a low viscosity.**



图 5

[21] **BN/N/2021/0066** [22] **21/06/2021**

[54] **Macromonomeric Stabilizer, Preparation Method Thereof, And Method For Preparing Polymeric Polyol**

[71] **WANHUA CHEMICAL GROUP CO., LTD of No. 17, Tianshan Rd YEDA Yantai, Shandong 264006, China**

[72] **1. LI, Fuguo**
2. JU, Changxun
3. LIU, Yang
4. QIN, Chengqun
5. LIU, BIN
6. WU, Xunkun
7. LI, Jing
8. SUN, YE
9. ZHENG, Bing
10. WANG, Lunpeng

[74] **Messrs. PINTAS CONSULTING GROUP SDN BHD of MIA Management Services, Anggerek Desa Complex, Bandar Seri Begawan BB3780, Brunei Darussalam**

[86] **PCT/CN2018/123892**

[87] **WO/2020/132940**

[51] **CO8G 18/63, CO8G 18/48**

[57] **Disclosed are a macromonomeric stabilizer, a preparation method thereof, a method for preparing a polymeric polyol using same, and the polymeric polyol prepared. Also disclosed are a soft polyurethane foam obtained by foaming a composition of the polymeric polyol prepared and a polyisocyanate, and a molded product comprising the soft polyurethane foam. The preparation method of the macromonomeric stabilizer comprises the following steps: reacting a polyol with a tricarboxylate not comprising a polymerizable ethylenically unsaturated double bond, or a derivative thereof, to form an adduct; and reacting the resulting adduct with an epoxide comprising a polymerizable ethylenically unsaturated double bond. The macromonomeric stabilizer of the present invention has a low viscosity, comprises a plurality of active sites, and canbe directly used in subsequent reactions. The preparation method of the macromonomeric stabilizer can be carried out under normal pressure, without the need for end-blocking with ethylene oxide. The polymeric polyol prepared using the macromonomeric stabilizer of the present invention has an excellent resistance to deformation at high temperatures.**



图 1

---

[21] BN/N/2021/0068 **[22]** 01/07/2021

[54] Imidazo[1,2-B]Pyridazine Il-17a Inhibitors

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46206-6288, United States of America

[72]
1. COATES, David Andrew
2. FRIMPONG, Kwame
3. HOLLOWAY, William Glen
4. JONES, Spencer Brian
5. LEVINSON, Adam Marc
6. LUGAR, Charles Willis III
7. RICHETT, Michael Enrico
8. WATSON, Brian Morgan
9. WOODMAN, Michael Edward

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. US62/789,247 Date: 07/01/2019 Country: United States of America
No. US62/842,770 Date: 03/05/2019 Country: United States of America

[86] PCT/US2020/012115

[87] WO/2020/146194

[51] CO7D 487/04, A61K 31/5025, A61P 17/06, A61P 37/00

[57] The invention provides certain difluorocyclohexy-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat

certain symptoms of psoriasis. rheumatoid arthritis or multiple sclerosis.



(II)

---

[21] BN/N/2021/0069 **[22]** 14/07/2021

[54] **Isolation And Cultivation Of Muscle And Fat Cells From Crustaceans**

[71] **SHIOK MEATS PTE. LTD. of 9 Chin Bee Drive, #05-01. Innovate 360, Singapore 619860**

[72] **1. SRIRAM, Sandhya**
2. LING, Ka Yi

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 10201900357Q Date: 15/01/2019 Country: Singapore
No. 62/856,479 Date: 03/06/2019 Country: United States of America

[86] **PCT/SG2020/050016**

[87] **WO/2020/149791**

[51] **C12N 5/07, Cl2N 15/63**

[57] **The present disclosure is directed to methods for the formation and production of renewable muscle and/or fat primary O cell lines. immortalized cell lines. and stem cell lines from shrimp. prawn, crab. crayfish. and/or lobster species and the cell lines themselves as well as human and animal consumable meat products produced therefrom.**

---

[21] BN/N/2021/0070 **[22]** 14/07/2021

[54] **Pcsk9 Inhibitors And Methods Of Use Thereof**

[71] **ASTRAZENECA AB of SE-151 85 Sodertalje, Sweden**

[72] **1. SERRANO-WU, Michael H.**
2. CHAMBERS, Mark
3. GOLDSMITH, Erica
4. TIERNEY, Jason
5. JANDU, Karamjit
6. CLARK, David
7. IHNCHLIFFE, Paul

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/794,234 Date: 18/01/2019 Country: United States of America

[86] **PCT/US2020/013881**

[87] **WO/2020/150473**

[51] **C07D 417/12, C07D 498/04, C07D 417/14, C07D 495/04, C07D 403/14, A61K 31/506, C07D 491/107, A61P 3/06, C07D 487/10, A61P 9/00, C07D 471/04**

[57] **The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases. and methods treating sepsis or septic shock. using the novel heterocyclic compounds disclosed herein.**

---

[21] **BN/N/2021/0071** **[22]** **27/07/2021**

[54] **Transportation Method And Apparatus**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 6 Shenton Way, #38-01 OUE Downtown, Singapore 068809**

[72] **1. GARG, Aayush**
2. PHANG, Chun Kai
3. AGARWAL, Chandan Kumar

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050042**

[87] **WO/2020/159431**

[51] **G06Q 10/02, GO6Q 50/28, G060 50/30**

[57] **A transportation system is made up by a plurality of contiguous geographical cells. The effective availability of service for transportation service users is calculated on the basis of the number of eligible transportation service providers located in one or more of the geographical cells. The calculations may take into account a distance between each service provider and the users.**



Fig 2

---

[21] **BN/N/2021/0072** **[22]** **29/07/2021**

[54] **Automatically Determining Optimal Transport Service Locations For Points Of Interest From Noisy Multimodal Data**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 6 Shenton Way, #38-01 OUE Downtown, Singapore 068809**

[72] **1. VARADARAJAN, Jagannadan**
2. TAN, Sien Yi
3. DUONG, Nguyen Duy

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050085**

[87] **WO/2020/167244**

[51] **H04W 4/02, GO6Q 50/30, G06Q 10/00**

[57] **A method, a computer-readable medium. and an apparatus for transport service are**

provided. The apparatus may receive a plurality of transport service transactions associated with a point of interest entity. For each transport service transaction. the apparatus may determine a transport service location at which the transport service transaction is executed. The apparatus may cluster the transport service locations determined for the plurality of transport service transactions. The apparatus may determine one or more candidate transport service locations for the point of interest entity based on the clustering. The apparatus may pros ide the one or more candidate transport service locations to a client or a service provider associated with a transport service transaction that is to be executed at the point of interest entity.



FIG. 8

---

[21] **BN/N/2021/0073** **[22]** **04/08/2021**

[54] **Alkyl Dihydroquinoline Sulfonamide Compounds**

[71] **AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799 United States of America**

[72] **1. WEISS, Matthew**
2. DINEEN, Thomas
3. MILGRAM, Benjamin C.

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/269,518 Date: 18/12/2015 Country: United States of America

[51] **C07D 403/12, C07D 413/12, A61K 31/4704, A61K 31/501, A61P 11/14, A61P 29/02**

[57] **The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.**

(I)



---

[21] **BN/N/2021/0074** **[22]** **05/08/2021**

[54] **Arginase Inhibitors And Methods Of Use Thereof**

[71] **ASTRAZENECA AB of SE-151 85 Sodertalje, Sweden**

[72] **1. MLYNARSKI, Scott Nathan**
2. GREBE, Tyler
3. KAWATKAR, Sameer
4. FINLAY, Maurice Raymond Verschoyle
5. SIMPSON, Iain

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/802,765 Date: 08/02/2019 Country: United States of America

[86] **PCT/IBS2020/050982**

[87] **WO/2020/161675**

[51] **A61P 29/00, A61K 31/69, A61P 35/00, C07F 5/02**

[57] **Disclosed are compounds of formula (Ib) or (Vc). or a pharmaceutically acceptable salt thereof. pharmaceutical compositions comprising, compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer. respiratory inflammatory**

disease_ and inhibiting arginase: wherein R^{I} is -II or -C(O)C11(R^{Ia})NHR^{Ib}: and R^{Ia} is selected from -II. -(C_1-C_4) alkyl and CH_2OR^{Ic}: R^{Ib} is -H: or alternatively, R^{Ia} and R^{Ib}, together with the atom to which they are attached. form a 5-membered heterocyclic ring; and R^{Ic} is H or -CH_3.

---

[21] BN/N/2021/0075 **[22]** 18/08/2021

[54] Herapeutic Antibody Formulation

[71] ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. CORVARI, Vincent John
2. PISUPATI, Karthik
3. SHI, Galen Huaiqiu

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/807,006 Date: 18/02/2019 Country: United States of America
No. 62/880,846 Date: 31/07/2019 Country: United States of America
No. 62/947,198 Date: 12/12/2019 Country: United States of America

[86] PCT/US2020/017594

[87] WO/2020/172002

[51] C07K 14/54, C07K 16/24, A61K 39/395, C07K 16/28, C07K 16/46, A61K 9/08, A61K 38/19, A61K 38/20

[57] Stable aqueous pharmaceutical formulations for therapeutic antibodies and methods of using such stable aqueous pharmaceutical formulations.

---

[21] BN/N/2021/0076 **[22]** 24/08/2021

[54] Fused Tricyclic Compounds Useful As Anticancer Agents

[71] ASTRAZENECA AB of SE-151-85 Södertälje, Sweden

[72] 1. KETTLE, Jason, Grant
2. SIMPSON, Iain

3. PHILLIPS, Christopher
4. BOYD, Scott
5. STEWARD, Oliver, Ross
6. BODNARCHUK, Michael, Steven
7. CASSAR, Doyle, Joseph
8. PIKE, Kurt, Gordon

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 61/813,885 Date: 05/03/2019 Country: United States of America
No. 63/951,146 Date: 21/12/2019 Country: United States of America

[86] **PCT/EP2020/055551**

[87] **WO/2022/178282**

[51] **G01S 7/481, H01F 7/02, G01R 33/00, G01R 33/02, G01D 5/12, G01S 17/931**

[57] **The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.**

---

[21] **BN/N/2021/0077** **[22]** **01/09/2021**

[54] **A Casing Cleaning Tool**

[71] **HAEFESTUS GLOBAL (FZE) of PO Box 66636, SHARJA, United Arab Emirates (previously was DRILLABLE BRUSH CO GLOBAL LTD)**

[72] **1. ALLEN, Anthony**

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 190547.6 Date: 17/04/2019 Country: United Kingdom

[86] **PCT/GB2020/050792**

[87] **WO/2020/212686**

[51] **E21B 37/02**

[57] **A NVCII cleaning tool (100) comprising: an elongate body (102) having a longitudinal axis: a central fluid bore (120) aligned with the longitudinal axis; and a cleaning element (110) mounted on the elongate body (102) and being displaceable with respect to the elongate body (102) in a direction inclined to the longitudinal axis. wherein the cleaning element (102) comprises at least one fluid channel (150) in fluid communication with the central fluid bore (120) and extending through the cleaning clement (110) in a direction inclined to the longitudinal axis.**



Fig. 1

---

[21] **BN/N/2021/0078** **[22]** **04/09/2021**

[54] **Compounds, Compositions, And Methods For The Treatment Of Disease**

[71] **F-STAR THERAPEUTICS, INC. of Eddeva B920 Babraham Research Campus Cambridge CB22 3AT, United Kingdom**

[72]
1. IYER, Radhakrishnan, P.
2. PADMANABHAN, Seetharamaiyer
3. BASKARAN, Subramanian
4. SHERI, Anjaneyulu
5. CLEARY, Dillon
6. MASTROLIA, Ron
7. ZHOU, Shenghua
8. CHALLA, Sreerupa

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/814,025 Date: 05/03/2019 Country: United States of America
No. 62/879,178 Date: 26/07/2019 Country: United States of America

[86] **PCT/US2020/021120**

[87] **WO/2020/181050**

[51] **A61K 31/519, A61K 31/4192, C07D 487/04**

[57] **Disclosed are compounds and compositions for inhibiting the expression ofa pattern recognition receptor (e.g., STING). and methods of use thereof.**

---

[21] **BN/N/2021/0079** **[22]** **13/09/2021**

[54] **Enhanced Method For Cutting Pipes On A Drill Floor And Tool Therefor**

[71] **CONTROL CUTTER AS of Energivegen 20, 4056 TANANGER, Norway**

[72] **1. BIRKELAND, Petter**
2. MJØLNE, Bård
3. SIREVÅG, Kjetil

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 20190418 Date: 27/03/2019 Country: Norway

[86] **PCT/NO2020/050054**

[87] **WO/2020/197401**

[51] **B23D 21/00, B23D 15/04, B21B 29/00**

[57] **The invention relates to a method and a cutting tool (100) for cutting a tubular structure (1) in the petrochemical industry. The method comprises the following steps: a) positioning the cutting tool (100) in a first position (P1) exterior to the tubular structure (1); b) squeezing the tubular structure (1) at the first position (P1) by activating a partial translational cutting movement of a non-rotatable cutting element (135) to obtain a dented region (D1) in the tubular structure (1); c) positioning the cutting tool (100) in a second position (P2) exterior to the tubular structure (1), wherein the second position (P2) is displaced over a predefined distance (dp) compared to the first position (P1), and d) cutting the tubular structure (1) at the second position (P2) by activating a full translational cutting movement of the non- rotatable cutting element (135) through the tubular structure (1). The invention renders time consuming pinning processes with multiple-pipe assemblies superfluous.**



Fig. 5c

---

[21] BN/N/2021/0080 **[22]** 21/09/2021

[54] **Method To Longitudinally And Circumferential Cut Out And Remove A Section Of A Wellbore Tubular**

[71] **AARBAKKE INNOVATION, A.S. of Forum Jaeren, P.O. Box 13, Bryne, N-4349, Norway**
PETROLIAM NASIONAL BERHAD of PETRONAS Twin Towers, Kuala Lumpur City, Centre Kuala Lumpur, 50088, Malaysia

[72] **1. HANSEN, Henning**
2. GUDMESTAD, Tarald
3. SHAFIEE, Luqmanul
4. RAHMAN, Siti

[74] **Messrs. MIRANDAH ASIA (SINGAPORE) PTE LTD of AIP LAW, Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/819,824 Date: 18/03/2019 Country: United States of America

[86] **PCT/1B2020/052426**

[87] **WO/2020/188481**

[51] **E21B 4/18, E21B 23/01, E21B 29/00, E21B 29/02, E21B 29/06**

[57] **A plug and abandonment wellbore intervention technology to longitudinal and circumferential cut a wellbore tubular (30) in the same wellbore intervention,**

followed by dropping the cut sections into the wellbore below the location of the lower circumferential cut, so that access to an external tubular (20) is possible for e.g. cement bond logging, placement of barrier material, removal of external tubular, etc.



FIG. 1

---

[21] BN/N/2021/0081 **[22]** 21/09/2021

[54] Communications Device, Method And Communications System For Managing A Plurality Of Data Structures

[71] GRABTAXI HOLDINGS PTE. LTD. of 3 MEDIA CLOSE, #01-03/06, SINGAPORE 138498

[72] 1. MADAAN, Yogesh
2. TEO, Yongkai

[74] Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[86] PCT/SG2019/050153

[87] WO/2020/190207

[51] G060 10/02, G06Q 50/30

[57] A communications device for managing a plurality of data structures, which is configured to observe a data stream for changes, the data stream having a plurality of data structures, each having an associated timestamp and data corresponding to a request relating to a job, filter, sequentially based on the associated timestamps, the data structures associated with requests causing the changes, wherein, for filtering, the communications device is configured, for each data structure, to query a database, if data corresponding to the job is in the database, determine, from the

data corresponding to the job, a status of the job, and determine, based on the status and the data of the data structure, whether the data of the data structure is valid data, and if there is no data corresponding to the job in the database, determine the data of the data structure as valid data, and process the valid data.



FIG. 3C

---

[21] BN/N/2021/0082 **[22]** 21/09/2021

[54] **Catalytic Conversion Method And System For Producing Gasoline And Propylene**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China**
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 8 Xueyuan Road, Haidian District, Beijing 100083, China

[72] **1. BAI, Xuhui**
2. ZUO, Yanfen
3. XU, Youhao
4. LUO, Yibin
5. SHU, Xingtian
6. WANG, Xieqing
7. WANG, Xin

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 201910224120.2 Date: 22/03/2019 Country: China

[86] **PCT/CN2020/079666**

[87] **WO/2020/192491**

[51] **C10G 55/06, C10G 57/02, C07C 11/06**

[57] **A catalytic conversion method and system for producing gasoline and propylene. Said method comprises: 1) subjecting a raw oil to a first catalytic conversion reaction in a first catalytic conversion reaction device to obtain a first reaction product; 2) separating the first reaction product to obtain a propylene fraction, a gasoline fraction, and a C4 olefin-containing fraction; 3) performing an oligomerization reaction on the C4 olefin-containing fraction in an oligomerization reactor to obtain a C12 olefin-containing oligomerization product,**



图 1

---

[21] **BN/N/2021/0083** **[22]** **21/09/2021**

[54] **Catalytic Conversion Process And System With Increased Propylene Production**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China**
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 8 Xueyuan Road, Haidian District, Beijing 100083, China

[72] **1. XU, Youhao**
2. BAI, Xuhui
3. WEN, Langyou
4. WANG, Xin
5. HE, Mingyuan

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 201910224119.X Date: 22/03/2019 Country: China

[86] **PCT/CN2020/079655**

[87] **WO/2020/192490**

[51] **C10G 55/06, C07C 4/06, C07C 11/06**

[57] **A catalytic conversion method and system for producing more propylene. The method comprises the following steps: 1) providing an initial raw material containing an olefin having four or more carbon atoms; 2) pre-treating the initial raw material to obtain a propylene precursor, the propylene precursor containing an olefin having 3×2^n carbon atoms, wherein n is an integer greater than or equal to 1; and subjecting the propylene precursor to a catalytic cracking reaction to obtain a reaction product containing propylene. The method and system can effectively improve the yield of propylene.**



图 1

---

[21] **BN/N/2021/0084** **[22]** **22/09/2021**

[54] **Pharmaceutical Composition, Comprising Human Hyaluronidase Ph20 Variant And Drug, For Subcutaneous Injection**

[71] **ALTEOGEN INC. of 62, Yuseong-daero 1628beon-gil Yuseong-gu Daejeon 34054 Republic of Korea**

[72] **1. PARK, Soon Jae**
2. CHUNG, Hye-Shin
3. LEE, Seung Joo
4. KIM, Kyuwan
5. BYUN, Minsoo
6. NAM, Ki Seok

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]

No. 10-2019-0033880 Date: 25/03/2019 Country: Republic of Korea

[86] **PCT/KR2020/003975**

[87] **WO/2020/197230**

[51] **A61K 9/00, A61K 47/42, A61K 39/395, A61K 45/06, A61P 35/00, C12N 9/26**

[57] **The present invention relates to a pharmaceutical composition comprising (a) a drug and (b) a human PH20 variant. The human PH20 variant contained in the pharmaceutical composition according to the present invention includes an amino acid substitution at one or more positions selected from the alpha helix 8 sequence (S347-C381) and a linkage region (A333-R346) between alpha helix 7 and alpha helix 8 on the wild-type human pH20 having the amino acid sequence of SEQ IS NO: 1, and is optionally cleaved at an amino acid positioned at the N-terminal or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable additive, particularly, a stabilizer. Due to the advantage of the human PH20 variant, the pharmaceutical composition according to the present invention can exhibit a maximum therapeutic effect of the drug used together therewith.**



---

[21] **BN/N/2021/0085** **[22]** **22/09/2021**

[54] **Heavy Chain Antibodies Binding To Psma**

[71] **TENEOBIO, INC. of 62, Yuseong-daero 1628beon-gil Yuseong-gu Daejeon 34054 Republic of Korea**

[72] **1. VAN SCHOOTEN, Wim**
2. CLARKE, Starlynn
3. DANG, Kevin
4. BUELOW, Ben

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/830,130 Date: 05/04/2019 Country: United States of America

[86] **PCT/US2020/026686**

[87] **WO/2020/206330**

[51] **C07K 16/30, C07K 16/28, A61K 39/395, A61P 35/00**

[57] **Anti-PSMA heavy chain antibodies (e.g., UniAbsTM are disclosed, along with methods of making such antibodies. CZ compositions. including pharmaceutical compositions, comprising such antibodies. and their use to treat disorders that are characterized by the expression of PSMA.**



FIG. 5A FIG. 5B FIG. 5C

---

[21] **BN/N/2021/0086** **[22]** **25/09/2021**

[54] **Estrogen Receptor Degrading Protacs**

[71] **ASTRAZENECA AB of 151 85 Södertälje, Sweden**

[72] **1. YANG, Bin**
2. HAYHOW, Thomas, George, Christopher
3. FALLAN, Charlene
4. SCOTT, James, Stewart
5. DIENE, Coura
6. BARLAAM, Bernard, Christophe
7. NISSINK, Johannes, Wilhelmus, Maria

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/825,924 Date: 29/03/2019 Country: United States of America

[86] **PCT/EP2020/058702**

[87] **WO/2020/201080**

[51] **C07D 471/04, A61K 31/437, A61K 31/506, A61P 35/00**

[57] **The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R^1, R2. R3, R, R, R7, R8, Linker, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.**

---

[21] **BN/N/2021/0087** **[22]** **27/09/2021**

[54] **Mirikizumab For Use In A Method Of Treating Crohn's Disease**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46206-6288, United States of America**

[72] **1. FRIEDRICH, Stuart William**
2. POLLACK, Paul Frederick
3. TUTTLE, Jay Lawrence

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/836,910 Date: 22/04/2019 Country: United States of America

[86] **PCT/US2020/028273**

[87] **WO/2020/219314**

[51] **A61K 39/395, A61P 1/00**

[57] **The present invention generally relates to the treatment of Crohns Disease with an anti-IL-23p19 antibody, particularly dosage regimens for the treatment of the disease.**



Average serum concentrations of mirikizumab during the induction period in the study described in Example 1.

Figure 1.

---

[21] **BN/N/2021/0088** **[22]** **27/09/2021**

[54] **Neuregulin-4 Compounds And Methods Of Use**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46206-6288, United States of America**

[72] **1. DAY, Jonathan Wesley**
2. HEUER, Josef George
3. MUPPIDI, Avinash
4. NI, Wei
5. PANCOOK, James David

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP LAW, Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/827,386 Date: 01/04/2019 Country: United States of America

[86] **PCT/US2020/025921**

[87] **WO/2020/205840**

[51] **C07K 14/475, A61 P 9/00, A6IK 38/18**

[57] **The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.**

---

[21] **BN/N/2021/0089** **[22]** **29/09/2021**

[54] **Supercapacitor**

[71] **VOLTA PTY LTD of 57B Newborough Street, Scarborough, Western Australia 6019, Australia**

[72] **1. LOSIC, Dusan**
2. ABDELSADIK, Mahmoud Moussa M.
3. DUBAL, Deepak

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 2019901067 Date: 29/03/2019 Country: Australia

[86] **PCT/AU2020/050294**

[87] **WO/2020/198784**

[51] **H01G 11/36, H01G 11/50, H01M 4/583, H01M 4/96, H01M 4/66, H01M 4/133, H01M 4/1393, C01B 32/15**

[57] **A lithium-ion hybrid supercapacitor comprising (i) an electrode comprising nitrogen-doped carbon nanotubes (N-CNTs), and (ii) an electrode comprising an electrically conductive graphene material. The supercapacitor can comprise an electrolyte which is a solution of (i) a lithium salt selected from $Li[PF_2(C_2O_4)_2]$, $Li[SO_3CF_3]$, $Li[N(CF_3SO_2)_2]$, $Li[C(CF_3SO_2)_3]$, $Li[N(SO_2C_2F_5)_2]$, $LiClO_4$, $LiPF_6$, $LiAsF_6$, $LiBF_4$, $LiB(C_6F_5)_4$, $LiB(C_6H_5)_4$, $Li[B(C_2O_4)_2]$, $Li[BF_2(C_2O_4)]$, and a mixture of any two or more thereof, and (ii) a solvent selected form dimethyl carbonate (DMC), ethyl methyl carbonate (EMC), diethyl carbonate (DEC), methyl propyl carbonate (MPC), ethyl propyl carbonate (EPC), ethylene carbonate (EC), propylene carbonate (PC), and a mixture of any two or more thereof.**



Figure 11

[21] BN/N/2021/0090 **[22]** 07/10/2021

[54] **Internet Of Things Architecture For Device Sharing**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. QI, Le**
2. YU, Zhixin
3. ZHENG, Alexis

[74] **Messrs. AIP LAW of Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050201**

[87] **WO/2020/209789**

[51] **G06Q 10/02, G06Q 50/30, B62K 11/00**

[57] **A method, a computer readable medium, and an apparatus for operating a motorized scooter are provided. The apparatus may be a part of the motorized scooter. The apparatus may receive an unlock request from a remote server. The apparatus may unlock itself in response to the unlock request. The apparatus may continuously upload its status to the remote server based on a schedule when it is unlocked. The apparatus may receive a lock request from the remote server. The apparatus may lock itself in response to the lock request.**



FIG. 1

[21] BN/N/2021/0091 **[22]** 07/10/2021

[54] **Threaded Coupling For Steel Pipe**

[71] **NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyodaku, Tokyo 100-8071, Japan**
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES 59620, France

[72] **1. INOSE, Keita**
2. SUGINO, Masaaki
3. UGAI, Shin
4. NAKANO, Hikari

[74] **Messrs. CCW PARTNERSHIP ADVOCATES & SOLICITORS of 1st & 2nd Floors, Units 9 & 10, Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE1318, Bandar Seri Begawan BS8674, Negara Brunei Darussalam**

[31][32][33]
No. 2019-147926 Date: 09/08/2019 Country: Japan

[86] **PCT/JP2020/030407**

[87] **WO/2021/029370**

[51] **F16L 15/04**

[57] **The purpose of the present invention is to provide a threaded coupling for a steel pipe with further improved seal performance, the threaded coupling having a two-stage screw including an intermediate seal and an intermediate shoulder. A pin (2) is provided with an inner seal part (22), an inner male screw part (23), an intermediate shoulder (24), an intermediate seal part (25), and an outer male screw part (26). A box (3) is provided with an inner seal part (32), an inner female screw part (33), an intermediate shoulder (34), an intermediate seal part (35), and an outer female screw part (36). The pin (2) includes a pin intermediate dangerous section PICCS located in the vicinity of the base end of the inner male screw part (23). The box (3) includes a box dangerous section BCCS located in the vicinity of the back-side end of the inner female screw part (33) and a box intermediate dangerous section BICCS located in the vicinity of the back-side end of the outer female screw part (36). The pin (2) and the box (3) satisfy the following relationship. PICCSA + BICCSA > BCCSA 0.70 ≤ PICCSA/BICCSA ≤ 0.95**

Fig. 1



---

[21] **BN/N/2021/0092** **[22]** **07/10/2021**

[54] **Building Frame, Building Frame Structure, Building Panel Structure, And Method For Constructing Building**

[71] **CDS NU STEEL HOMES INTERNATIONAL LTD. of Asakusaraiichi Bldg. 614, 19-17, Kaminarimon 2-chome, Taito-ku, Tokyo 1110034, Japan**

[72] **1. SAWADA, Taiichi**

[74] **Messrs. CCW PARTNERSHIP ADVOCATES & SOLICITORS of 1st & 2nd Floors, Units 9 & 10, Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah BE1318, Bandar Seri Begawan BS8674, Negara Brunei Darussalam**

[86] **PCT/JP2018/023246**

[87] **WO/2019/244232**

[51] **E04C 3/06, E04C 2/42, E04C 5/18**

[57] **[Problem] To provide a building frame for constructing a building, the frame being stronger than reinforced concrete, and being able to be relatively easily assembled at a construction site, without skills, and within a short time. [Solution] Provided are a building frame and the like, the building frame being characterized by comprising: U-shaped parts that are arranged left and right so as to sandwich a center space in a cross-sectional view; and a connection part that connects top portions, on the center side, of the left and right U-shaped parts so as to form a reverse U-shaped part, wherein the longitudinal edges, on the far side from the center, of the U-shaped parts arranged left and right in the cross-sectional view are shorter than the longitudinal edges, on the center side, connected by the connection part.**



---

[21] **BN/N/2021/0093** **[22]** **09/10/2021**

[54] **Distributed In-Memory Spatial Data Store For K-Nearest Neighbour Search**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. ZHANG, ZHIYIN**
2. HUANG, XIAOCHENG
3. SUN, CHAOTANG
4. ZHENG, SHAOLIN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[86] **PCT/CN2019/082349**

[87] **WO/2020/206665**

[51] **G08G 1/00**

[57] **A database system is configured to enable fast searching for neighbours nearest to a mobile object located in a geographical space made up of plural spatially distinct subspaces, each being made up of plural cells. The database system has an operating system controlling storage of object data amongst the plural storage nodes, to represent one or more spatially distinct subspaces, in a respective single one of the storage nodes. Location data of each object is used to index that object with respect to cells making up each spatially distinct subspace in each node.**



FIG 2

---

[21] BN/N/2021/0094 **[22]** 09/10/2021

[54] Electric Personal Mobility Device

[71] GRABTAXI HOLDINGS PTE. LTD. OF 3 MEDIA CLOSE, #01-03/06, SINGAPORE 138498

[72] 1. WU, XIHU
2. YAN, KANG
3. YU, PENGFEI
4. ZHENG, YI

[74] Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 201910292447.3 Date: 12 April, 2019 Country: China

[86] PCT/SG2020/050206

[87] WO/2020/209792

[51] B60L 53/80, B60L 53/64, B60K 1/04, H01M 2/10, B62K 11/02

[57] A electric personal mobility device may include a main body including a rider-support-platform structure and a steering column coupled to the rider-support-platform structure. The electric personal mobility device may further include a wheel arrangement, having at least one front wheel and at least one rear wheel, supporting the main body. The at least one front wheel may be steerable by the steering column. According to various embodiments, the rider-support-platform structure may include an elongate hollow housing structure enclosing an internal space partitioned to define

a first and second longitudinal-internal-battery-compartments. Each longitudinal-internal-battery-compartment may be extending lengthwise along respective longitudinal side of the elongate hollow housing and having a respective rear opening at an aft portion of the elongate hollow housing structure. The rider-support-platform structure may include a rear-wheel-fork fixedly extending longitudinally from the aft portion between the rear openings. The rear-wheel-fork may be holding the at least one rear wheel.



FIG. 1A

---

[21] BN/N/2021/0095 **[22]** 12/10/2021

[54] Pyrrolotriazine Derivatives For Treating Kit- And Pdgfra-Mediated Diseases

[71] BLUEPRINT MEDICINES CORPORATION of 45 Sidney Street Cambridge, MA 02139 Massachusetts United States of America

[72] 1. KIM, JOSEPH, L.
2. DINEEN, THOMAS, A.
3. GUZI, TIMOTHY

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/833,529 Date: 12 April, 2019 Country: United States of America
No. 62/911,016 Date: 04 October, 2019 Country: United States of America
No. 62/930,240 Date: 04 November, 2019 Country: United States of America

[86] PCT/US2020/027177

[87] WO/2020/210293

[51] **C07D 487/04, A61P 35/00, A61K 31/53**

[57] **The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.**



(I)

---

[21] **BN/N/2021/0096** **[22]** **23/10/2021**

[54] **Process For Treating Thermally Converted Gasolines**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China**
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, SINOPEC of 18 Xueyuan Road, Haidian District Beijing 100083, China

[72] **1. WANG, XIN**
2. SUN, XIN
3. XU, YOUHAO
4. HE, MINGYUAN

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[51] **C10G 55/06**

[57] **The invention relates to a thermal conversion gasoline treatment method, which comprises: cutting a thermal conversion gasoline raw material to obtain a light gasoline fraction and a heavy gasoline fraction, feeding the heavy gasoline fraction into a pre-lifting section of a catalytic cracking reactor, and contacting with a**

regenerated catalyst to carry out a first reaction, a cracking material flow of the first reaction and a catalyst mixture enter a first reaction zone of the reactor to be subjected to a second reaction together with the heavy raw oil, and a cracking material flow of the second reaction and a catalyst mixture enter a second reaction zone of the reactor to be subjected to a third reaction together with the light gasoline fraction; the reaction oil gas and the spent catalyst are separated, the spent catalyst is recycled after being regenerated in a regenerator, the reaction oil gas is delivered to a fractionation system, and a product containing clean gasoline is obtained. The method reduces the sulfur content and olefin content of the thermal conversion gasoline, and improves the octane number of the thermal conversion gasoline.



---

[21] BN/N/2021/0097 **[22]** 27/10/2021

[54] 3-Amino-4h-Benzo[E][1,2,4]Thiadiazine 1,1-Dioxide Derivatives As Inhibitors Of Mrgx2

[71] SOLENT THERAPEUTICS, LLC of 59 Magus Avenue Welleslet, Massachusetts 02481 United States of America

[72]
1. BIGI, SIMONE
2. CHAMBERS, ALLISON, L.
3. GIBSON, TONY
4. PICKENS, JASON
5. SWANN, STEVE
6. VASSAR, ANGIE
7. ZHOU, FENG
8. KONO, MITSUNORI
9. SETO, MASAKI
10. SHIOKAWA, ZENYU

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/840,344 Date: 29 April, 2019 Country: United States of America

[86] **PCT/US2020/030305**

[87] **WO/2020/223255**

[51] **C07D 285/32, C07D 417/04, C07D 417/12, C07D 417/14, A61P 19/02, A61K 31/5415**

[57] **Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.**



---

[21] **BN/N/2021/0098** **[22]** **27/10/2021**

[54] **Communications Server Apparatus, Methods And Communications Systems For Recommending One Or More Points-Of-Interest For A Transport-Related Service To A User**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72]
1. FAN, QING
2. JIAO, LANG
3. DAI, CHENGCHENG
4. DENG, ZIQIANG
5. ZHANG, RUI

[74] **Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/CN2019/084965**

[87] **WO/2020/220188**

[51] **G01C 21/34, G06Q 50/30**

[57] **Provided are communications server apparatus for recommending one or more points-of-interest (POIs) for a transport-related service to a user, such as when the user wish to request or make a booking for a transport-related service. The POIs are recommended at different actions/scenarios or at different stages of the booking, based on a plurality of data/information, which may be from a plurality of data sources. Recommendation may be done using data relating to one or more pairings of origin locations and destination locations corresponding to historical transport-related services, or using historical data and data corresponding to top ranking points-of-interest in at least one destination category in a geographical area, or based on resultant scores of candidate POIs that are determined from individual scores assigned to a plurality of criteria for the candidate POIs, where the individual scores for at least some of the criteria are determined based on historical data.**



FIG. 2B

---

[21] **BN/N/2021/0099** **[22]** **28/10/2021**

[54] **Itaconic Acid Derivatives And Uses Thereof In Treating An Inflammatory Disease Or A Disease Associated With An Undesirable Immune Response**

[71] **SITRYX THERAPEUTICS LIMITED of S10, Magdalen Centre, 1 Robert Robinson Avenue, Oxford Science Park, Oxford Oxfordshire OX4 4GA, United Kingdom**

[72] **1. COOKE, MICHAEL LIAM**
2. COUSIN, DAVID
3. FYFE, MATTHEW COLIN THOR
4. TEOBALD, BARRY JOHN
5. THOM, STEPHEN MALCOLM
6. WAUGH, THOMAS MICHAEL

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP Law, Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 19172051.5 Date: 30 April, 2019 Country: European Patent Office
No. 19189910.3 Date: 02 August, 2019 Country: European Patent Office
No. 19217846.5 Date: 19 December, 2019 Country: European Patent Office
No. 20162494.7 Date: 11 March, 2020 Country: European Patent Office

[86] **PCT/GB2020/051060**

[87] **WO/2020/222011**

[51] **C07C 69/593, A61P 29/00, A61K 31/19, A61K 31/194, C07C 69/003, C07C 69/013, C07C 69/608, C07C 69/66, C07C 69/74, C07C 211/40, C07C 309/12, C07C 309/23, C07C 309/24, C07C 309/27**

[57] **The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.**



(IW-1)

---

[21] **BN/N/2021/0100** **[22]** **28/10/2021**

[54] **Process For The Production Of An Additive For Bituminous Conglomerates With High Mechanical Performances And Additive Composition**

[71] **ITERCHIMICA S.P.A. of VIA G. Marconi, 21 24040 Suisio Italy**

[72] **1. GIANNATTASIO, FEDERICA**
2. CISANI, SERGIO
3. BERTULETTI, ELISA

[74] **Messrs. HENRY GOH & CO SDN BHD of AIP Law, Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 102019000006600 Date: 07 May, 2019 Country: Italy

[86] **PCT/EP2020/062260**

[87] **WO/2020/225184**

[51] **C08J 3/12, C08J 3/00, B29B 17/00, B29B 17/04, C08L 95/00, E01C 7/26**

[57] **The present invention refers to a process for the production of an additive composition intended to be mixed into bituminous conglomerate for road paving, in other words a mixture of polymers and additives which can be used in the modification of bituminous conglomerates, bitumen and bituminous products, such as bituminous membranes, in order to provide resilience to the bituminous preparations, starting from a mixed waste material containing a mixture of plastic materials, wherein said mixture of plastic materials comprises at least one plastic material based on a polyolefin thermoplastic polymer, grinding to a particle size of 20-40 mm, washing, separating a portion of plastic material having an average density of 1.0 kg/m3 or lower and comprising the polyolefin thermoplastic polymer, grinding said plastic portion to a particle size of 10-20 mm, mixing it with PVB and further grinding to a particle size of 4-6 mm. Also additive composition obtainable by this process.**

---

[21] **BN/N/2021/0101** **[22]** **06/11/2021**

[54] **Punch And Inject Tool For Downhole Casing And Method For Use Thereof**

[71] **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. of Carel van Bylandtlaan 30 NL-2596 The Hague Netherlands**

[72] **1. CORNELISSEN, ERIK KERST**
2. CORNELISSEN, IRIS
3. OLIEUX, ROBBE IBN
4. VAN MOORSEL, SAM GERARD

[74] **Messrs. DREW AND NAPIER LLC of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 19174667.6 Date:15 May, 2019 Country: European Patent Office

[86] **PCT/EP2020/063116**

[87] **WO/2020/229440**

[51] **E21B 33/13, E21B 43/112**

[57] **A downhole tool, which includes a tool housing having a longitudinal axis, is equipped**

with a sting for punching a hole in a casing wall and injecting a sealant though said hole. The tube has a fluid channel to establish fluid communication from within the tool housing to an exterior of the tool housing through the fluid channel. A press device acts on the sting to force the sting in a radially outward direction from the tool housing. A check valve is arranged in the fluid channel, which allows fluid communication in a direction from within the tool housing to an exterior of the tool housing and which blocks fluid flow in an opposite direction. In use, the sting can perforate a casing wall and the sealant can be injected into an annular space around the casing.



FIG. 1

---

[21] BN/N/2021/0102 **[22]** 10/11/2021

[54] Punch And Inject Tool For Downhole Casing And Method For Use Thereof

[71] DECIPHERA PHARMACEUTICALS, LLC of 200 Smith Street, Waltham, Massachusetts 02451, United States of America

[72] 1. FLYNN, DANIEL, L.
2. AHN, YU, MI
3. CALDWELL, TIMOTHY
4. VOGETI, LAKSHMINARAYANA

[74] Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/846,251 Date: 10 May, 2019 Country: United States of America
No. 62/846,258 Date: 10 May, 2019 Country: United States of America
No. 62/911,728 Date: 07 October, 2019 Country: United States of America
No. 62/911,730 Date: 07 October, 2019 Country: United States of America

[86] PCT/US2020/032087

[87] WO/2020/231806

[51] **C07D 403/12, C07D 403/14, C07D 471/08, C07D 487/04, C07D 487/08, A61P 35/00, A61K 31/506, A61K 31/444**

[57] **Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.**



(I)

---

[21] **BN/N/2021/0103** **[22]** **10/11/2021**

[54] **Heteroarylaminopyrimidine Amide Autophagy Inhibitors And Methods Of Use Thereof**

[71] **DECIPHERA PHARMACEUTICALS, LLC of 200 Smith Street, Waltham, Massachusetts 02451, United States of America**

[72] **1. FLYNN, DANIEL, L.**
2. AHN, YU, MI
3. CALDWELL, TIMOTHY
4. VOGETI, LAKSHMINARAYANA

[74] **Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/846,260 Date: 10 May, 2019 Country: United States of America
No. 62/846,264 Date: 10 May, 2019 Country: United States of America
No. 62/911,733 Date: 07 October, 2019 Country: United States of America
No. 62/911,736Date: 07 October, 2019 Country: United States of America

[86] **PCT/US2020/032090**

[87] **WO/2020/231808**

[51] **C07D 403/12, C07D 403/14, A61P 35/00, A61K 31/506, A61K 31/4439**

[57] **Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.**



Formula I

---

[21] **BN/N/2021/0104** **[22]** **13/11/2021**

[54] **Steel Pipe Threaded Coupling**

[71] **NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-8071 Japan**
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES, 59620 France

[72] **1. UEBA, Hidetoshi**
2. MURAKAMI, TARO

[74] **Messrs. CCW PARTNERSHIP of Unit Nos. 9 & 10 2th Floor, Lebuhraya Sultan Hassanal Bolkiah, Block C, Kiarong Complex, BE1318, Brunei Darussalam**

[31][32][33]
No. 2019-159375 Date: 02 September, 2019 Country: Japan

[86] **PCT/JP2020/031462**

[87] **WO/2021/044862**

[51] **F16L 15/06, E21B 17/042**

[57] **The present invention provides a threaded coupling, for a steel pipe having a large diameter size, which can provide high torque-resistance performance and high sealing performance, and which has shear-resistance performance corresponding to the size of the steel pipe to be linked. A steel pipe threaded coupling 1 has: a tubular pin 10 provided to a tip section of a steel pipe 2 having a large diameter size; and a tubular box 20 into which the pin 10 is screwed and which is fastened to the pin 10. The pin 10 has male threads 11 comprising tapered threads. The box 20 has female threads 21 comprising tapered threads. The male threads 11 and the female threads 21 are wedge-shaped threads in which the thread ridge span gradually narrows, the cross-**

sectional shape of the thread ridges being dove-tailed. The male threads 11 are designed to satisfy the following formula so that the thread ridge span at a thread terminus end on the tip side is of a size matching the size of a pipe body of the steel pipe 2. 0.4≤{(DW+2TH)2-DW2}×Wmin/(OD2-ID2)≤0.6

Fig. 3



---

[21] BN/N/2021/0105 **[22]** 15/11/2021

[54] **Method, Data Processing Apparatus And Computer Program Product For Determining Road Intersections**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. YIN, YIFANG**
2. VARADARAJAN, JAGANNADAN
3. SUNDERRAJAN, ABHINAV
4. ZIMMERMANN, ROGER

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050507**

[87] **WO/2021/071422**

[51] **G06K 9/00, G06N 20/00**

[57] **A method, data processing apparatus, and computer code for identifying road intersections includes providing location data obtained from at least one vehicle's trajectory, wherein the location data may include geographical data within a geographical perimeter. The method includes determining node vectors by applying a geographical descriptor model on a target location included in the geographical perimeter. The geographical descriptor model includes a plurality of multiscale node descriptors including a target multiscale descriptor and neighboring multiscale descriptors. Each of the plurality of multiscale node descriptors includes at least two**

shape descriptors of different geographical resolution. Each of the neighboring locations is at a respective geographical distance from the target location. The node vectors may be respectively determined for each of the plurality of multiscale node descriptors. The method includes inputting the node vectors into a trained multiscale classifier including a graph convolutional network to provide a probability of the target location being a road intersection.



FIG. 1

---

[21] **BN/N/2021/0106** **[22]** **15/11/2021**

[54] **Controller, Electric Power System Comprising The Controller, Method Of Operating The System, And Vehicle Comprising The System**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498**

[72] **1. WU, XIHU**
2. ZHANG, HE
3. JIANG, LEI
4. ZHENG, YI

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 201910894637.2 Date: 20 September, 2019 Country: China

[86] **PCT/SG2020/050385**

[87] **WO/2021/054892**

[51] **H02J 7/00, H01M 10/44, B60L 58/22**

[57] **An electric power system (10) for an electric vehicle (300), including: first charging and discharging current paths (101C, 101D) connected to a first battery unit (20);**

second charging and discharging current paths (102C, 102D) connected to a second battery unit (30); third charging and discharging current paths (103C, 103D) for a connection with an electric control system (40) of the vehicle (300); a first power switch (111) between the first discharging current path (101D) and the third discharging current path (103D); a second power switch (112) between the second discharging current path (102D) and the third discharging current path (103D); a controlling unit (120) to set the first and second power switches (111, 112) based on states of the accumulators, at least one of the first and second battery units (20, 30) being swappable. A controller (100), a method, and a vehicle (300) comprising the system (10) are also disclosed.



FIG. 1

---

[21] BN/N/2021/0107 **[22]** 15/11/2021

[54] **Enclosure Assembly For Vehicle, Method Of Mounting, And Vehicle Including The Enclosure Assembly**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498**

[72] **1. TSE, YAT MING**
2. WANG, SHI QIAN
3. LIM, CHEE KOON
4. SONG, GUO DONG

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 201910893472.7 Date: 20 September, 2019 Country: China

[86] **PCT/SG2020/050395**

[87] **WO/2021/054893**

[51] **B62H 5/00, B65D 50/06, B65D 55/10**

[57] **Aspects concern an enclosure assembly (100) for mounting on a tube of a vehicle, methods of mounting the assembly on a vehicle, and a vehicle including the assembly. The assembly (100) comprises a clamping portion (110) comprising a concave portion (111) for at least partially surrounding the tube (210) and a flange portion (112) at one end of the concave portion (111); a holding support plate (120) including a first side for facing the tube and a second side opposite thereto, the first side configured to be attached to the flange portion (112) by a fastening means (130) solely operable from the second side of the holding support plate (120) at a position of operability; a housing (140) comprising a cavity for receiving an electronic circuit (150) and a lower portion to be attached to the second side of the holding support plate (120). The housing (140) overlaps said position of operability.**



FIG. 1

---

[21] **BN/N/2021/0108** **[22]** **15/11/2021**

[54] **Antenna Design Of Internet Of Things For Sharing Scooter**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498**

[72] **1. WANG, SHIQIAN**
2. SONG, GUODONG
3. FAN, RUNFA
4. YU, ZHIXIN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050422**

[87] **WO/2021/040611**

[51] **H01Q 1/32, B62K 3/00, B62K 11/00**

[57] **In one aspect, a scooter is provided. The scooter may include a steering column. The scooter may include a rider-support-platform coupled to the steering column. The**

scooter may include an antenna attached to the steering column. The antenna may be configured to perform wireless communication. The antenna may have a first inclination angle relative to the steering column. In another aspect, a method of providing a scooter is provided. The method may include providing a steering column of the scooter. The method may include coupling a rider-support-platform to the steering column. The method may include attaching an antenna to the steering column.



FIG. 2

---

[21] BN/N/2021/0109 [22] 15/11/2021

[54] Communications Server Apparatus, Communications Device(S) And Methods Of Operation Thereof

[71] GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498

[72] 1. WIDDOWS, DOMINIC

[74] Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811 Brunei Darussalam

[86] PCT/SG2019/050266

[87] WO/2020/231323

[51] G06F 40/274, G06F 40/10

[57] A communications server apparatus (100) is configured to receive (202) text data comprising at least one text data element associated with an abbreviated text unit. The text data element is compared (204) with a plurality of candidate text data elements from a representation of a given text database, each candidate text data element associated with a respective candidate text unit in the database. Values for a similarity measure between the at least one text data element and the candidate text data elements are determined (206), and candidate text data elements are processed (208) to select candidate text data elements with associated candidate text units having an ordered relationship with the abbreviated text unit. The similarity measure values

and the candidate text data element selections are used (210) to nominate an associated candidate text unit as a disabbreviated text unit for the abbreviated text unit.



Fig 5

---

[21] **BN/N/2021/0110** **[22]** **15/11/2021**

[54] **Methods And Data Processing Systems For Predicting Road Attributes**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498**

[72] **1. YIN, Yifang**
2. VARADARAJAN, Jagannadan
3. WANG, Guanfeng
4. ZIMMERMANN, Roger

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2020/050046**

[87] **WO/2021/154155**

[51] **G01C 21/26, G06N 3/02, G06N 3/08**

[57] **The disclosure relates to a method of predicting one or more road attributes. The method may include providing trajectory data of a geographical area. The method may further include providing map data, wherein the map data may include image data of the geographical area. The method may further include extracting trajectory features from the trajectory data and extracting map features from the map data. The method may further include using at least one processor to predict road attributes by inputting the trajectory features and the map features in a neural network and by classifying an output of the neural network into prediction probabilities of the road attributes. The disclosure also relates to a data processing system; to a non-transitory computer-readable medium storing computer executable code; and to a method of**

training an automated predictor.



FIG. 3

---

[21] BN/N/2021/0111 **[22]** 15/11/2021

[54] **Communications Server Apparatus And Method For Deriving A Quantum Modifier For A Transport-Related Service**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, SINGAPORE 138498**

[72]
1. XU, XIN
2. WILSON, PADARN GEORGE
3. XIE, CHAO
4. CAO, YANG
5. KUMAR, PRASHANT

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2019/050267**

[87] **WO/2020/231324**

[51] **G06Q 50/30, G06Q 10/06, G06Q 30/04**

[57] **A communications server apparatus for deriving a quantum modifier for a quantum related to a transportation service, the communications server apparatus comprising a processor and a memory, and being configured, under control of the processor to execute instructions in the memory: to receive user service request data comprising data indicative of a user pick-up location and data indicative of a user drop-off location, to record a user pick-up time and to generate one or more data records comprising: an index idle time data field comprising data indicative of an index idle time at plural notional drop-off locations; and a user drop-off time data field comprising data indicative of a user drop-off time; to retrieve, from a database, data indicative of a service provider's estimated idle time for the user drop-off location at the user drop-off time; to compare the data indicative of the index idle time and the data indicative of the service provider's estimated idle time and generate a comparison result data field comprising data indicative of a comparison result; and to**

generate, in the one or more data records, a data field comprising quantum modifier data indicative of the quantum modifier based on the data indicative of the comparison result.



Fig. 1

---

[21] BN/N/2021/0112 **[22]** 16/11/2021

[54] Screw-Threaded Joint

[71] NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 100-8071 Japan
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES, 59620 France

[72] 1. OKU, YOUSUKE
2. MARUTA, SATOSHI
3. SUGINO, MASAAKI
4. FOTHERGILL, ALAN

[74] Messrs. CCW PARTNERSHIP of Unit Nos. 9 & 10, 2th Floor, Lebuhraya Sultan Hassanal Bolkiah Block C, Kiarong Complex, BE1318, Brunei Darussalam

[31][32][33]
No. 2019-172936 Date: 24 September, 2019 Country: Japan

[86] PCT/JP2020/031453

[87] WO/2021/059807

[51] F16L 15/04

[57] The purpose of the present invention is to improve the productivity of a screw-threaded joint having a two-stage screw structure including an intermediate shoulder surface by facilitating machining of the intermediate shoulder surface and by preventing cracking near an intermediate critical cross-section under tensile load. On the outer circumference of a pin 2 between an intermediate shoulder surface 24 and a second male screw 27 of the pin 2, a circumferential direction groove 25 having a curved surface 25a smoothly continuous with the intermediate shoulder surface 24 is

provided, and thus plastic strain that occurs near a pin intermediate critical cross-section PICCS is reduced. Further, on the inner circumference of a box 3 between an intermediate shoulder surface 35 and a first female screw 32 of the box 3, a circumferential direction groove 34 having a curved surface 34a smoothly continuous with the intermediate shoulder surface 35 is provided, and thus plastic strain that occurs near a box intermediate critical cross-section BICCS is reduced.



---

[21] BN/N/2021/0113 **[22]** 20/11/2021

[54] Solid State Forms

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799 United States of America

[72]
1. CHAVES, MARY
2. LOPEZ, PATRICIA
3. AGARWAL, PRASHANT
4. AMEGADZIE, ALBERT
5. AZALI, STEPHANIE
6. SHIMANOVICH, ROMAN
7. KELLY, RON C.
8. REID, DARREN LEONARD

[74] Messrs. SPRUSON & FERGUSON PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/851,044 Date: 21 May, 2019 Country: United States of America

[86] PCT/US2020/033831

[87] WO/2020/236947

[51] C07D 471/04, A61P 35/00, A61K 31/519

[57] The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-

fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

FIG. 1



---

[21] **BN/N/2021/0114** **[22]** **20/11/2021**

[54] **Pyrrolidine Compounds**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46206-6288 United States of America**

[72] **1. LAFUENTE BLANCO, CELIA**
2. DIAZ BUEZO, NURIA
3. MARTINEZ PEREZ, JOSE ANTONIO
4. SANZ GIL, GEMA CONSUELO
5. PRIEGO SOLER, JULIAN

[74] **Messrs. SPRUSON & FERGUSON PTE LTD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 19382477.8 Date: 07 June, 2019 Country: European Patent Office

[86] **PCT/US2020/035825**

[87] **WO/2020/247429**

[51] **C07D 401/12, C07D 401/14, A61K 31/4025, A61P 3/10**

[57] **The present invention provides compounds of the Formula (I) wherein L is selected from the group consisting of -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, (II) and (III), or a pharmaceutically acceptable salt thereof; a compound of the formula: (IV), processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.**



---

[21] BN/N/2021/0115 **[22]** 02/12/2021

[54] **Low Cost And Sanitary Efficient System And Method That Creates Two Different Treatment Zones In Large Water Bodies To Facilitate Direct Contact Recreational Activities**

[71] **CRYSTAL LAGOONS TECHNOLOGIES, INC. of 2 Alhambra Plaze Penthouse 1B Coral Gables, Florida 33134 United States of America**

[72] **1. FISCHMANN, FERNANDO BENJAMIN**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 16/456,762 Date: 28 June, 2019 Country: United States of America

[86] **PCT/US2020/034909**

[87] **WO/2020/263488**

[51] **C02F 1/32, C02F 1/52, C02F 1/54**

[57] **The present invention discloses designating two different treatment zones in a large body of water. The first zone is a sedimentation zone. This zone is used mainly to provide treatment and settling of microorganisms and/or contaminants to inactivate and/or remove them from the water body. In this zone a disinfection method based on a CT index and applying an efficient amount of a flocculant composition may be used. The second zone is a dissipation zone. This zone is where main direct contact recreational water activities are intended to occur. In the dissipation zone a water flow is established that, along with the natural currents produced by winds and/or water temperature differences, generate a water dissipation pattern of the volume of water within the dissipation zone into the sedimentation zone. In addition, continuous**

disinfection of the water volume in the dissipation zone is preferably provided by maintaining a permanent chlorine residual.

Figure 1



---

[21] BN/N/2021/0116 **[22]** 04/12/2021

[54] **Method For Processing Gene Sequencing Data And Apparatus For Processing Gene Sequencing Data**

[71] **BGI GENOMICS CO., LTD. of Floor 7-14, Building No.7, BGI Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong 518000, China**
BGI HEALTH (HK) COMPANY LIMITED of M/F, 16 Dai Fu Street, Tai Po Industrial Estate, N.T., Hong Kong 999077, China

[72] **1. ZHANG, YOUJIN**
2. YU, CHUANG
3. KONG, LINGXIANG
4. HE, HUI
5. HE, ZENGQUAN
6. JIN, XIANGQIAN

[74] **Messrs. HENRY GOH & CO. SDN. BHD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 202011139823.4 Date: 22 October, 2020 Country: China

[86] **PCT/CN2020/127101**

[87] **WO/2022/082879**

[51] **G16B 30/10, G06F 13/42, G06F 9/50**

[57] **The embodiments of the disclosure provide a method for processing gene sequencing data. The method is applied to an apparatus for processing gene sequencing data. The apparatus includes an advanced RISC machine, ARM, architecture, a graphics processing unit, GPU, architecture, and a peripheral component interconnect, PCI,**

bus; the ARM architecture includes at least one central processing unit, CPU, module; the GPU architecture includes at least one GPU module. The method includes: obtaining, by a CPU module in an idle state, batches of gene sequencing data by reading gene sequencing data in batches; obtaining, by the CPU module in the idle state, a first algorithm and a second algorithm by dividing a gene analyzing method; obtaining, by the CPU module in the idle state, a plurality of reads by dividing each batch of gene sequencing data based on the first algorithm, and sending the plurality of reads and the second algorithm to a GPU module in an idle state; performing, by the GPU module in the idle state, a calculation on each read based on the second algorithm, and sending respective calculation results to the CPU module in the idle state; and obtaining, by the CPU module in the idle state, a batch processing result based on the calculation results and the first algorithm. This method divides the analyzing method to run parts of the method on the CPU module and the GPU module, which greatly improves data analyzing efficiency.



图 1

30 PCI bus

---

[21] BN/N/2021/0117 **[22]** 04/12/2021

[54] Human Phenotypic Standard Term Determination Method, And Related Device

[71] BGI GENOMICS CO., LTD. of Floor 7-14, Building No.7, BGI Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong 518000, China
BGI HEALTH (HK) COMPANY LIMITED of M/F, 16 Dai Fu Street, Tai Po Industrial Estate, N.T., Hong Kong 999077, China

[72] 1. ZHOU, JIAN
2. KONG, LINGXIANG
3. YANG, JIAOBO
4. HE, ZENGQUAN
5. WANG, JIN'AN

[74] Messrs. HENRY GOH & CO. SDN. BHD. of AIP LAW, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei

Darussalam

[31][32][33]
No. 202010265146.4 Date: 07 April, 2020 Country: China

[86] **PCT/CN2020/127048**

[87] **WO/2021/203694**

[51] **G06F 40/117**

[57] **A human phenotypic standard term determination method, and a related device. The method comprises: obtaining symptom description information (S100); performing query matching on word segmentation groups corresponding to various human phenotypic standard terms in a pre-set human phenotypic standard term library and the symptom description information, and determining the degree of matching between each human phenotypic standard term and the symptom description information (S200), wherein the word segmentation group comprises at least one segmented word list obtained by means of performing, according to a pre-set word segmentation rule, word segmentation on human phenotypic standard terms corresponding to the word segmentation group, and the segmented word list comprises at least one segmented word; and determining a human phenotypic standard term, the degree of matching of which meets a pre-set matching success condition (S300). According to the method, query matching is performed on symptom description information and word segmentation groups corresponding to various human phenotypic standard terms, and a human phenotypic standard term conforming to the symptom description information is screened out, thereby facilitating research and communication of the symptom description information by a technician, and also facilitating data analysis and mining of symptoms on the symptom description information.**



图 1

---

[21] **BN/N/2021/0118** **[22]** **09/12/2021**

[54] **Method, Server And Communication System Of Verifying User For Transportation Purposes**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. DONG, CHEUK LUN**
2. WONG, CHUN TUNG
3. ABEDIN, MUNIRUL
4. NYON, YEE WON

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[86] **PCT/SG2020/050052**

[87] **WO/2021/158168**

[51] **G06F 21/32, G06K 9/46, G06F 3/01**

[57] **A method of verifying a user for transportation purposes is disclosed. The method may include using a communication apparatus to detect a face of the user. The method may include using the communication apparatus to instruct the user to perform a specific action, to validate that the specific action is performed by the user, to extract a frame from the specific action to use as an image, to obtain image parameters from the frame and to use the communication apparatus to send the image to a server for the server to determine whether the image is a genuine face by comparing the image parameters of the image with parameters in a database to obtain a comparison result and to use the comparison result to determine if the user should be verified.**



FIG. 1

[21] **BN/N/2021/0119** **[22]** **11/12/2021**

[54] **System And Method For Partitioning Geographical Areas Into Logistical Areas For Dynamic Pricing**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. YAN, WEILI**
2. LI, WENTONG
3. WANG, CHEN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2020/050081**

[87] **WO/2021/167525**

[51] **H04W 4/02, G06Q 10/04, G06Q 50/30, G06F 16/29**

[57] **A method for partitioning a geographic area, including: partitioning the geographic area into geographic units; for each respective geographic unit: determining, a central location of the respective geographic unit; determining, an aggregate demand location of the respective geographic unit based on pick-up locations in the respective geographic unit in a time period; determining, an aggregate supply location of the respective geographic unit based on provider locations when responding to requests having pick-up locations in the respective geographic unit in said time period; for each respective pair of geographic units, determining, among a plurality of the geographic units, a connection strength between the respective pair based on distance metrics between the respective pair, where the distance metrics are determined based on the central locations, the aggregate supply locations, and the aggregate demand locations of the respective pair in said time period; and assigning each respective geographic unit to a respective one of one or more aggregate geographic units based on the determined connection strengths.**



FIG. 9

[21] **BN/N/2021/0120** **[22]** **11/12/2021**

[54] **Swappable Battery Pack**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. YAN, KANG**
2. LV, YANHUA
3. WU, XIHU
4. ZHANG, HE

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2020/050142**

[87] **WO/2021/188041**

[51] **H01M 2/10, B62M 6/90, B60L 53/80**

[57] **Aspects concern a battery pack for mounting on a vehicle. The battery pack may comprise an elongated cell rack comprising one or more battery cells arranged therein. The battery pack may comprise a tubular battery case at least partially surrounding the elongated cell rack. The battery pack may comprise a top seal cover sealing a top portion of the elongated cell rack. The battery pack may comprise a bottom seal cover arranged at a bottom portion of the elongated cell rack. The battery pack may comprise a female pin receptacle arranged on the bottom seal cover at the bottom portion of the elongated cell rack.**



FIG. 1

[21] BN/N/2021/0121 [22] 11/12/2021

[54] **Method Of Predicting Fare And Fare Prediction Data System**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. QIU, XUEHENG**
2. LI, WENTONG
3. WANG, CHEN

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2020/050124**

[87] **WO/2021/183039**

[51] **G06Q 50/30, G06N 3/08**

[57] **An aspect of the disclosure relates to a fare prediction data system and a method of predicting fare for transportation services, the method including: receiving, at a server, from a digital device, a request including a service time; calculating a predicted fare at the server; and sending the predicted fare from the server to the digital device. Calculating the predicted fare uses the service time, a long term surge prediction and a short term surge prediction as input in a fare estimator. The long term surge prediction may be calculated using a long term surge predictor (LTSP) and the short term surge prediction may be calculated using a short term surge predictor (STSP). The LTSP uses historical data, and the STSP uses the historical data and recent data which may be more recent than the historical data. Other aspects related to surge prediction systems, methods, and computer products including instructions for carrying out the any of the methods.**



FIG. 1A

[21] **BN/N/2021/0122** **[22]** **11/12/2021**

[54] **Demand Notification Device, Computing Device And Demand Notification Method**

[71] **GRABTAXI HOLDINGS PTE. LTD. of 3 Media Close, #01-03/06, Singapore 138498**

[72] **1. WANG, Xueou**
2. HOOI, Bryan Kuen-Yew
3. WENG, Renrong
4. KAKAR, Pravin Vinodkumar
5. NG, See Kiong
6. HSU, Wynne

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[86] **PCT/SG2020/050112**

[87] **WO/2021/177892**

[51] **G06Q 10/04, G06Q 50/30, G06Q 10/02, G06Q 10/08, G06Q 30/02, G06N 3/08**

[57] **Aspects concern a demand notification device (110), comprising: a determining unit (122) configured to determine a quantity of a demand of a transport service for a plurality of users (102, 104, 106) having a predetermined area as destination in a first time period, the quantity of the demand indicating how many users of the plurality of users are determined to desire to travel into the predetermined area; and wherein the determining unit (122) is further configured to determine a real space service demand from a plurality of users (102, 104, 106) to be fulfilled in the predetermined area in a second time period, wherein the real space service is provided by a service provider (120); an analysis unit (124) configured to determine a predicted real space service demand in a third time period for the predetermined area based on the quantity of users (102, 104, 106) in the predetermined area at the first time period and the demand of real space service in the predetermined area in the second time period and further configured to monitor the predicted real space service demand in the third time period in the predetermined area regarding a threshold value of service demand for the predetermined area at the third time; and a notification unit (126) configured to submit a notification to the real space service provider (120) in case the predicted real space service demand is beyond the threshold value.**



FIG. 1

---

[21] **BN/N/2021/0123** **[22]** **13/12/2021**

[54] **Cementing And Sand Control System And Methodology**

[71] **SCHLUMBERGER TECHNOLOGY B.V. of Parkstraat 83 The Hague 2514 JG Netherlands**

[72] **POIZAT, JEREMIE**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/861,201 Date: 13 June 2019 Country: United States of America

[86] **PCT/US2020/036996**

[87] **WO/2020/252021**

[51] **E21B 43/14, E21B 43/26, E21B 23/08, E21B 34/10, E21B 43/04**

[57] **A technique facilitates downhole operations, e.g. gravel packing and cementing operations, in a borehole. According to an embodiment, a service tool is releasably coupled with respect to a casing. The casing is used to run the service tool downhole into a borehole. In some embodiments, the casing is connected with a downhole completion, e.g. a sand control completion. A work string may then be conveyed downhole to the service tool and connected to the service tool. While connected to the work string, the service tool may be operated to perform desired downhole operations.**



FIG. 1

---

[21] **BN/N/2021/0124** **[22]** **13/12/2021**

[54] **Method For Optimizing A Fermentation Process**

[71] **UNIBIO A/S of Langebjerg 1, Roskilde, 4000, Denmark**

[72] **1. NANDY, SUBIR KUMAR**
2. PETERSEN, LEANDER
3. CHRISTENSEN, IB

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. DKPA 2019 00697 Date: 07 June 2019 Country: Denmark
No. DKPA 2019 01279 Date: 31 October 2019 Country: Denmark

[86] **PCT/EP2020/065347**

[87] **WO/2020/245197**

[51] **C12N 1/20, C12N 1/30, A23K 10/10**

[57] **The present invention relates to a process for cultivating one or more microorganisms capable of metabolising methane, the process comprises the steps of: (i) adding a fermentation medium to a fermentation reactor; (ii) adding the one or more microorganism to a fermentation reactor, providing an inoculated fermentation medium, wherein the one or more microorganism does not include a recombinant microorganism; (iii) adding a C1-C5 carbon source, e.g. methane, to the fermentation reactor and/or the inoculated fermentation medium during the fermentation of the one or more microorganisms; and (iv) optionally, adding oxygen to the fermentation reactor and/or the inoculated fermentation medium during the fermentation of the**

one or more microorganisms, wherein the oxygen is added to the fermentation reactor and/or the inoculated fermentation medium to provide a content of undissolved oxygen in the fermentation reactor and/or a content of gaseous oxygen in an exhaust gas is at most 5% (vol/vol).



---

[21] BN/N/2021/0125 **[22]** 13/12/2021

[54] **Method For Controlling A Fermentation Process**

[71] **UNIBIO A/S of Langebjerg 1, Roskilde, 4000, Denmark**

[72] **1. NANDY, SUBIR KUMAR**
2. PETERSEN, LEANDER

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. DKPA 2019 00714 Date: 13 June 2019 Country: Denmark

[86] **PCT/EP2020/066198**

[87] **WO/2020/249670**

[51] **CJ2N 1/30, Cl 2M 1/34, Cl2M 1/04**

[57] **The present invention relates to a fermentation process for the fermentation of at least one microorganism, wherein the fermentation process comprises the steps of (a) allowing a fermentation broth comprising the at least one microorganism to flow in the fermentation reactor; (b) supplying a carbon-substrate to the fermentation reactor allowing the gaseous carbon-substrate to be dissolved, or partly dissolved, in the fermentation broth; (c) supplying a nitrogen-substrate to the fermentation reactor allowing the gaseous nitrogen-substrate to be dissolved, or partly dissolved, in the fermentation broth; and (d) maintaining a nitrate concentration of the fermentation broth below 0.035 g/l, and/or maintaining a nitrate concentration of the fermentation broth below 0.01 g nitrate/g biomass; wherein the at least one methanotrophic**

organism comprises at least one methanotrophic microorganism.



Fig. 1

---

[21] BN/N/2021/0126 **[22]** 14/12/2021

[54] **Disubstituted Pyrazole Compounds As Ketohexokinase Inhibitors**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana, 46206-6288, United States of America**

[72]
1. COATES, DAVID ANDREW
2. DURHAM, TIMOTHY BARRETT
3. JOHNSTON, RICHARD DUANE
4. MASSEY, STEVEN MARC
5. SPINAZZE, PATRICK GIANPIETRO
6. STACK, DOUGLAS RICHARD
7. TOTH, JAMES LEE

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/862,382 Date:17 June 2019 Country: United States of America
No. 62/975,887 Date: 13 February 2020 Country: United States of America

[86] **PCT/US2020/037894**

[87] **WO/2020/257171**

[51] **C07D 401/14, C07D 403/14, A61K 31/506, A61K 31/4439, A61P 3/10, A61P 9/00, A61P 13/12**

[57] **The present invention provides a compound of Formula I: or a pharmaceutically**

acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.



---

[21] BN/N/2021/0127 **[22]** 14/12/2021

[54] Processing Route Information

[71] GRABTAXI HOLDINGS PTE. LTD. of 6 Shenton Way, #38-01 OUE Downtown, 068809, Singapore

[72] 1. YANG, LIUQIN
2. WENG, RENRONG
3. ZHANG, SIZHE

[74] Messrs. AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[86] PCT/SG2019/050319

[87] WO/2020/263176

[51] GOIC 21/34, G060 50/30, G06010/04

[57] Server apparatus comprising a processor and a memory, the server apparatus being configured, under control of the processor, to execute instructions stored in the memory: to establish a route data record comprising data indicative of plural routes, each said route being between a start location and a respective destination, whereby each respective destination has at least one route to it from said start location; to process the route data record to determine a zone data record indicative of zones making up each route; and to combine the zone data record with a prediction data record to score the route data making up each said route to each destination based upon a prediction of the probability of a job or expected revenue in each zone making up that route.



FIGURE 8

---

[21] **BN/N/2021/0128** **[22]** **16/12/2021**

[54] **Pharmaceutical Compositions For Glucagon And GLP-1 Co-Agonist Peptides**

[71] **MEDIMMUNE LIMITED of Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom**

[72] **GOMES DOS SANTOS, ANA, LUCIA**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/869,263 Date: 01 July 2019 Country: United States of America

[86] **PCT/EP2020/068411**

[87] **WO/2021/001374**

[51] **A61K 38/26, A61P 3/08, A61P 3/06, A61P 3/04, A61P 1/16**

[57] **The present invention provides formulations for parenteral administration of GLP-1/Glucagon agonist peptides, methods of making such formulations, and methods of treatment using such formulations.**



Molecular Formula: $C_{167}H_{252}N_{42}O_{55}$
Molecular Weight: 3728.03618
HisSerGlnGlyThrPheThrSerAspLys[Glu.C(O)C16]SerGluTyrLeuAspSer
GluArgAlaArgAspPheValAlaTrpValGluAlaGlyGly (SEQ ID NO:1)

FIG. 1

---

[21] **BN/N/2021/0129** **[22]** **16/12/2021**

[54] **Aminopyrimidine Amide Autophagy Inhibitors And Methods Of Use Thereof**

[71] **DECIPHERA PHARMACEUTICALS, LLC of 200 Smith Street, Waltham Massachusetts, 02451, United States of America**

[72] **1. FLYNN, DANIEL, L.**
2. AHN, YU, MI
3. CALDWELL, TIMOTHY
4. VOGETI, LAKSHMINARAYANA

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/862,469 Date: 17 June 2019 Country: United States of America
No. 62/862,470 Date: 17 June 2019 Country: United States of America
No. 62/911,739 Date: 07 October 2019 Country: United States of America
No. 62/911,740Date: 07 October 2019 Country: United States of America

[86] **PCT/US2020/037906**

[87] **WO/2020/257180 Al**

[51] **A61P 35/00, CO7D 403/12, CO7D 239/48, CO7D 403/14, CO7D 401/12, AGIK 31/506, C07D 401/14**

[57] **Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.**

---

[21] **BN/N/2021/0130** **[22]** **18/12/2021**

[54] **Method And Device For Determining A Degree Of Gene Association**

[71] **BGI GENOMICS CO., LTD of Floors 7-14, Building No. 7, Bgi Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong, 518000, China**
BGI HEALTH (HK) COMPANY LIMITED of M/F, 16 Dai Fu Street, Tai Po Industrial Estate, N.T., Hong Kong 999077, China

[72] **1. ZHOU, JIAN**
2. KONG, LINGXIANG
3. WANG, JINAN

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]
No. 202011535972.2 Date: 23 December 2020 Country: China

[86] **PCT/CN2021/073013**

[87] **WO/2022/134252**

[51] **G06F 16/33, G06F 40/295, G06K 9/62, G16H 50/70, G16B 50/00**

[57] **The present application discloses a method and device for determining a degree of gene association. Through determining record data of target association record(s) of a disease description entry and a plurality of genes in each preset association database, inputting the record data into a preset entry-gene association matrix, and determining an association score of the disease description entry with respective to each of the plurality of genes in the preset association database, the degrees of association between the disease description entry and the plurality of genes can be rapidly obtained.**



Fig. 1

---

[21] **BN/N/2021/0131** **[22]** **21/12/2021**

[54] **Shared Memory Based Gene Analysis Method, Apparatus And Computer Device**

[71] **BGI GENOMICS CO., LTD of Floors 7-14, Building No. 7, Bgi Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong, 518000, China**
BGI HEALTH (HK) COMPANY LIMITED of M/F, 16 Dai Fu Street, Tai Po Industrial Estate, N.T., Hong Kong 999077, China

[72] **1. YANG, JIAOBO**
2. SONG, CHAO
3. YU, CHUANG
4. ZHANG, YOUJIN
5. HE, ZENGQUAN
6. WANG, JIN´AN

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 202011139824.9 Date: 22 October 2020 Country: China

[86] **PCT/CN2020/127072**

[87] **WO/2022/082878**

[51] **G16B 50/00, G06F 9/54**

[57] **A shared memory based gene analysis method, apparatus and computer device. The method comprises: reading sample data and preprocessing the sample data; performing a gene analysis on the sample data preprocessed, and determining whether a required library file in the gene analysis is in a gene shared memory; if yes, obtaining the required library file from the gene shared memory, mapping the required library file to a process of the gene analysis of the sample data preprocessed, and completing the genea corresponding analysis. In this method, a shared memory mechanism is adopted to establish indexes for the gene analysis. Whether a library file that are frequently used in the gene analysis process are in the gene shared memory is determined; if yes, the library file can be obtained from the gene shared memory, and can be conveniently mapped from the gene shared memory to an analysis process performed on the sample data. The method can greatly reduce the time and I/O occupation for loading the library file from a hard disk. Therefore, the efficiency of analysis can be improved.**



图 2

S202 Read sample data, and preprocess the sample data
S204 Perform gene analysis on the preprocessed sample data, and determine whether a required library file is in a gene shared memory of a gene analysis library file in the gene analysis process
S206 If yes, obtain the library file from the gene shared memory, map the library file to the gene analysis process of the sample data, and complete corresponding analysis

[21] BN/N/2021/00132 **[22]** 21/12/2021

[54] Fast-Built Testing Laboratory For Medical Testing

[71] BGI GENOMICS CO., LTD of Floors 7-14, Building No. 7, Bgi Park, No. 21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong, 518000, China
BGI HEALTH (HK) COMPANY LIMITED of M/F, 16 Dai Fu Street, Tai Po Industrial Estate, N.T., Hong Kong 999077, China

[72] 1. YIN, YE
2. TANG, MEIFANG
3. ZENG, HAO
4. HUANG, TIANXUN
5. SUO, MAN
6. ZHANG, DONG
7. LIU, XING
8. CHEN, WURONG
9. LI, NING
10. LI, WENQI
11. CAO, SUJIE

[74] Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. CN202022482114.8 Date: 02 November 2020 Country: China

[86] PCT/CN2020/136382

[87] WO/2022/088421

[51] E04H 3/08, E04H 1/12, B01L 1/00

[57] Provided is a fast-built testing laboratory for medical testing. The fast-built testing laboratory includes a plurality of cabins. The plurality of cabins is fast-built cabins and forms one or more testing chains. Each testing chain includes: a sample unpacking zone (1); a sampling zone (2); a sample extraction zone (3); and a nucleic acid amplification and testing zone (4). For each testing chain, extraction reagents and amplification reagents are provided by a reagent preparation zone (5). A cabin quantity of the plurality of cabins is adjustable for adapting to a testing throughput of the fast-built testing laboratory.



111 Unpacking compartment A 15 people
112 Unpacking compartment F 15 people
113 Unpacking compartment H 15 people
114 Unpacking compartment O 15 people
121 Sampling compartment B 15 people
122 Sampling compartment G 15 people
123 Sampling compartment L 15 people
124 Sampling compartment P 15 people
131 Extraction compartment C 6 people
132 Extraction compartment D 6 people
133 Extraction compartment M 6 people
134 Extraction compartment Q 6 people
141 Amplification compartment E 4 people
142 Amplification compartment R 4 people
15 Reagent preparation compartment N 6 people
17 Unpacking and sampling integrated compartment S 4 people
AA Sample flow direction
BB People flow and material flow direction
CC Waste flow direction
DD Area I
EE Area II
FF Area III
GG Supply area
HH Sample area 22 people

图 9

---

[21] **BN/N/2021/0133** **[22]** **28/12/2021**

[54] **Glucagon-Like Peptide 1 Receptor Agonists**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana, 46285, United States of America**

[72] **1. COATES, DAVID ANDREW**
2. FIELDS, TODD
3. HO, JOSEPH DANIEL
4. QU, FUCHENG

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/868,117 Date: 28 June 2019 Country: United States of America
No. 62/904,906 Date: 24 September 2019 Country: United States of America

[86] **PCT/US2020/038617**

[87] **WO/2020/263695 Al**

[51] **A6IK 314-139, A61P 3/10, CO7D 405/14**

[57] **In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.**



(I)

[21] BN/N/2021/0134 **[22]** 28/12/2021

[54] Method For Recovering Energy Of Electric Vehicle

[71] GUANGDONG GOBAO ELECTRONIC TECHNOLOGY CO., LTD of No. 3 West Industry Road, Songshan Lake High-tech Industry, Development Zone, Dongguan, Guangdong 523000, China

[72] 1. CHEN, QINGFU
2. ZHOU, LESHUAN
3. JIAN, RUIQIAN
4. YU, XIAOBO

[74] Messrs. CCW PARTNERSHIP of Units 9 & 10, 2nd Floor, Block C, Kiarong Complex, Lebuhraya Sultan Hassanal Bolkiah, Bandar Seri Begawan BE1318, Brunei Darussalam

[31][32][33]
No. 202010345912.8 Date: 27 April 2020 Country: China

[86] PCT/CN2020/095685

[87] WO/2021/217796

[51] B62M 6/45

[57] Disclosed in the present invention is a method for recovering energy of an electric vehicle. The method comprises the following steps of: S1, acquiring the opening degree L of a steering handle and the rotating speed n of a motor by means of sampling, and determining the opening degree L of the steering handle; S2, according to the opening degree L of the steering handle, calculating the current target torque T** of the steering handle by means of a steering handle-torque control algorithm; A3, according to the rotating speed n of the motor, calculating the current target braking torque T by means of a speed-torque control algorithm; and S4, according to the current target braking torque T, controlling the torque of the motor to change from a current value to a target value so as to complete energy recovery. The present invention can determine a driver's demand for braking strength according to the opening degree of the steering handle and the speed of the driver in loosening the steering handle, and can adjust energy recovery power and the braking strength according to the state of the opening degree of the steering handle, thereby reducing the operation processes of the driver and reducing operation fatigue while improving the driving experience of the driver.



---

[21] **BN/N/2022/0001** **[22]** **03/01/2022**

[54] **Compounds And Methods Of Use Thereof As Antibacterial Agents**

[71] **MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, United States of America**

[72] **1. CROWLEY, BRENDAN M.**
2. NANTERMET, PHILIPPE
3. OLSEN, DAVID
4. SUZUKI, TAKAO

[74] **Messrs. SPRUSON & FERGUSON PTE LTD., c/o AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. PCT/CN2019/094601 Date: 03 July 2019 Country: China

[86] **PCT/CN2020/093887**

[87] **WO/2021/000684**

[51] **C07D 261/04, C07D 413/10, C07D 413/12, C07D 413/04, C07D 417/10, A61K 31/42**

[57] **Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R 1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.**



(I)

---

[21] BN/N/2022/0002 **[22]** 04/01/2022

[54] Combination Of Ibuprofen And Tramadol For Relieving Pain

[71] FARMALÍDER, S.A. of La Granja, 1 Alcobendas, Madrid E-28108, Spain

[72]
1. PORTOLÉS PÉREZ, ANTONIO
2. SANTÉ SERNA, LUIS NARCISO
3. SALAS BUTRÓN, MARÍA DEL ROSARIO
4. VARGAS CASTRILLÓN, EMILIO
5. CALANDRIA PÉREZ, CARLOS
6. HORCAJADA CÓRDOBA, RAQUEL
7. MUÑOZ RUIZ, ÁNGEL JOSÉ
8. VICARIO DE LA TORRE, MARTA
9. SANZ MENÉNDEZ, NURIA
10. GÓMEZ CALVO, ANTONIA
11. SÁNCHEZ GARCÍA, JOSE ANGEL
12. DUART GONZALEZ, ESTER
13. GARCÍA ALONSO, FERNANDO

[74] Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. EP19382583.3 Date: 09 July 2019 Country: European Patent Office

[86] PCT/EP2020/069306

[87] WO/2021/005129 Al

[51] A61K 31/192, A61P 29/00, A6IK 31/135, A61K 9/16, A61K 9/00

[57] The present invention relates to the combination of ibuprofen in the form of a pharmaceutically acceptable salt, and tramadol, or a pharmaceutical acceptable salt thereof, for use in the treatment of pain in humans, wherein the dosage of ibuprofen in the combination is comprised between 350 mg and 450 mg and the dosage of tramadol is comprised between 35 mg and 40 mg, expressed as equivalent weight of

tramadol hydrochloride. The combination is suitable for the treatment of moderate to severe pain, of chronic or acute origin, and is particularly effective for those patients suffering from more intense pain. It also relates to a pharmaceutical composition comprising said fixed-dose combination of ibuprofen and tramadol.



FIGURE 1

---

[21] **BN/N/2022/0003** **[22]** **06/01/2022**

[54] **Dose Dumping Resistant Pharmaceutical Compositions Comrising Verinurad**

[71] **ASTRAZENECA AB of SE-151 85 Sodertalje, Sweden**

[72] **1. VON CORSWANT, CHRISTIAN**
2. MALEKI, LALEH

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]
No. 62/874,691 Date: 16 July 2019 Country: United States of America

[86] **PCT/EP2020/069941**

[87] **WO/2021/009197 Al**

[51] **A61K 9/50, A61K 47/36, A61K 31/44, A61K 31/519, A61P 13/12, A61K 31/4418**

[57] **Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods.**



FIG. 1

---

[21] **BN/N/2022/0004** **[22]** **08/01/2022**

[54] **Device And Method For Processing A Conduit**

[71] **CALLIDUS CAPITAL B.V. of Rottumerweg 19 8445 PA Heerenveen The Netherlands**

[72] **1. VEENSTRA, FEITZE**

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. NL2023460 Date: 08 July 2019 Country: The Netherlands

[86] **PCT/NL2020/050445**

[87] **WO/2021/006732**

[51] **E2IB 29/00, FI6L 1/028**

[57] **A first aspect provides a device for processing a conduit. The device comprises a cutting module to cut at least part of the conduit over a longitudinal axis of the conduit by creating a first cut line in the conduit substantially parallel to the longitudinal axis, a separation module arranged to separate a first part of the conduit on a first side of the first cut line from a second part of the conduit on a second side of the first cut line and a transportation module for driving the conduit along the cutting module and the separation module. The transportation module is used to pull the piping of the ground, irrespective of whether the piping is in the ground positioned in a vertical way, a horizontal way or under an angle. Hence, the transportation module may be implemented as an extraction module for extracting the piping from the ground.**



---

[21] **BN/N/2022/0005** **[22]** **08/01/2022**

[54] **Processes And Intermediate For The Large-Scale Preparation Of 2,4,6-Trifluoro-N-[6-(1-Methyl-Piperidine-4-Carbonyl)-Pyridin-2-Yl]-Benzamide Hemisuccinate, And Preparation Of 2,4,6-Trifluoro-N-[6-(1-Methyl-Piperidine-4-Carbonyl)-Pyridin-2-Yl]-Benzamide Ac**

[71] **ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana, 46285, United States of America**

[72] **1. ABURUB, Aktham**
2. COATES, David, Andrew
3. FRANK, Scott, Alan
4. KERR, Mark, Steven
5. ROTHHAAR, Roger, Ryan
6. VAID, Radhe, Krishan

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]
No. US62/871,965 Date: 09 July 2019 Country: United States of America

[86] **PCT/US2020/040881**

[87] **WO/2021/007155**

[51] **A61K 31/444, A61P 25/06, C07D 401/06**

[57] **The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-**

pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.



---

[21] BN/N/2022/0006 **[22]** 11/01/2022

[54] **Process For The Preparation Of Sterile Ophthalmic Aqueous Fluticasone Propionate Form A Nanocrystals Suspensions**

[71] **NICOX OPHTHALMICS, INC. of 4721 Emperor Blvd. Suite 260, Durham, North Carolina 27703, United States of America**

[72] **1. BUKOWSKI, JEAN-MICHEL**
2. NADKARNI, AKSHAY
3. BOYER, JOSÉ L.
4. DUQUESROIX-CHAKROUN, BRIGITTE
5. NAVRATIL, TOMAS

[74] **Messrs. MARKS & CLERK SINGAPORE LLP c/o AIP LAW of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. US62/877,599 Date: 23 July 2019 Country: United States of America
No. US62/942,551 Date: 02 December 2019 Country: United States of America

[86] **PCT/IB2020/056832**

[87] **WO/2021/014348**

[51] **A61K 9/14, A61K 9/10, A61K 47/02, A61K 47/10, A61K 31/573, A61P 27/00, C07J 31/00, C07J 71/00**

[57] **The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.**

Figure 1



---

[21] **BN/N/2022/0007** **[22]** **11/01/2022**

[54] **Threaded Connection For Casing String Of An Oil Well**

[71] **VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES 59620, France**
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1008071, Japan

[72] **1. FOULOGNE, ANTHONY**
2. MARTIN, PIERRE
3. ABDEDDAIM, MALIC
4. PUSARD, MICKAËL

[74] **Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. FR1908203 Date: 19 July 2019 Country: France

[86] **PCT/EP2020/069949**

[87] **WO/2021/013646 Al**

[51] **E21B 17/042, F16L 15/00, F16L 15/06**

[57] **Threaded tubular connection for the casing of hydrocarbon wells obtained by makeup**

of a male tool joint with a female tool joint, the connection comprising in this order from a free edge (19) of the male tool joint: an inner metal-metal seal (25, 26), a first threaded portion (16a, 18a), an intermediate abutment (22, 24), an intermediate metal-metal seal (27, 28) and a second threaded portion (16b, 18b), the free edge (19) being at a non-zero axial distance (d) from the female tool joint, the threaded portions each comprising a helix equipped with a load flank, a thread crest, a stabbing flank, a thread root, such that a pitch of the load flank (LFLp1, LFLb1) and a pitch of the stabbing flank (SFLp1, SFLb1) of the first threaded portion, and respectively a pitch of the load flank (LFLp2, LFLb2) and a pitch of the stabbing flank (SFLp2, SFLb2) of the second threaded portion fulfil the following condition: [Math 12] SFLb1 = LFLb1 = SFLb2 = LFLb2 = SFLp1 = LFLp1 = SFLp2 = LFLp2.

Fig. 3



---

[21] BN/N/2022/000 **[22]** 11/01/2022

[54] Threaded Connection Having A Dissymmetrical Helical Profile

[71] VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES 59620, France
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1008071, Japan

[72] 1. OSHIMA, MASAHIRO
2. KIMOTO, MASANARI

[74] Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. FR1908204 Date: 19 July 2019 Country: France

[86] PCT/EP2020/069948

[87] WO/2021/013645 Al

[51] E21B 17/042, F16L 15/00, F16L 15/06

[57] **Threaded tubular connection for the casing of hydrocarbon wells obtained by makeup of a male tool joint with a female tool joint, the connection comprising a threaded portion (16a, 18a), such that the male and respectively female threaded portions each comprise a helix provided with a load flank, a thread crest, a stabbing flank, a thread root, such that a pitch of the load flank (LFLp, LFLb) and a pitch of the stabbing flank (SFLp, SFLb) fulfils the following condition: [Math 22] SFLb = LFLb = SFLp = LFLp = k, A tooth width (Wtp) of the male helix and a tooth width of the female helix (Wtb) are such that [Math 23] or [Math 24] and [Math 25] Wtp + Wtb < k**

$$50\% < \frac{Wtp}{Wtb} < 80\% \quad \text{[Math 23]}$$

$$50\% < \frac{Wtb}{Wtp} < 80\% \quad \text{[Math 24]}$$

Fig. 14



---

[21] **BN/N/2022/0013** **[22]** **12/01/2022**

[54] **Preparation Method For Propylene Epdxidation Catalyst And Use Thereof**

[71] **WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, 264000 Shandong, China**

[72] **1. WANG, LEI**
2. WANG, TONGJI
3. YE, FEI
4. SUN, KANG
5. CHU, NAIBO
6. LI, YUAN
7. LI, YUAN

[74] **Messrs. PINTAS IP GROUP SDN BHD, No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Bandar Seri Begawan BE1318, Brunei Darussalam**

[86] **PCT/CN2020/072098**

[87] **WO 2021/142635**

[51] **B01J 23/28, C07D 301/12, C07D 303/04**

[57] **Disclosed are a method for preparing a catalyst for epoxidation of propylene and the use thereof. During the preparation, a catalyst for epoxidation of propylene is obtained by mixing a formulated alkoxide solution of active components and a silica**

gel carrier, and then subjecting same to a rotary evaporation treatment to remove low carbon alcohols, so as to obtain a catalyst precursor, and then subjecting the resulting catalyst precursor to roasting and silanization treatments. The catalyst has a simple preparation process, can be applied to the chemical process of preparation of propylene oxide by means of propylene epoxidation, and has a high average selectivity for propylene oxide and industrial application prospects.

---

[21] **BN/N/2022/0014** **[22]** **12/01/2022**

[54] **Far-Infrared (Fir) Emitting Particles Embedded Compression Garment For The Limbs**

[71] **BE INTERNATIONAL MARKETING SDN BHD of C-20-G, Jalil Link 2 No. 5, Jalan Jalil Perkasa 1, Bukit Jalil, 57000 Kuala Lumpur, Malaysia**

[72] **1. LEE, SUET SEN**
2. HO, HUEY CHUIN
3. OH, SIANG HWA

[74] **Messrs. PINTAS IP GROUP SDN BHD, No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Bandar Seri Begawan BE1318, Brunei Darussalam**

[31][32][33]
No. MYPI 2019003908 Date: 05 July 2019 Country: Malaysia

[86] **PCT/MY2020/050047**

[87] **WO/2021/006721**

[51] **A41B 11/00, A61F 13/08, A61N 5/06**

[57] **The present invention relates to a compression garment designed for improving body fluid circulation and also provides foot arch support. More particularly, the garment being derived from fabric embedded with far-infrared (FIR) emitting particles and wherein said garment comprises at least two distinct zones each of which is adapted to surround a limb of the user and achieve said compressive effect, one of the distinct zones comprises a lower leg section which is elasticated so as to provide a first compressive effect, when worn, and another zone of the distinct zones comprising a foot section which is elasticated between toe and heel portions of the foot section so as to provide a second compressive effect, when worn.**



Figure 1

---

[21] BN/N/2022/0015 **[22]** 12/01/2022

[54] **Method For Treating Production Wastewater From The Preparation Of Propylene Oxide By Co-Oxidation**

[71] **WANHUA CHEMICAL GROUP CO., LTD. of No. 17, Tianshan Rd, YEDA, Yantai, 264000 Shandong, China**

[72] **1. FAN, ZHENLONG**
2. DONG, YANFENG
3. ZENG, FANXUE
4. YE, JIANCHU
5. LENG, BINGWEN
6. YU, GENHAI
7. HE, XINCHUN
8. ZHANG, HONGKE

[74] **Messrs. PINTAS IP GROUP SDN BHD, No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Bandar Seri Begawan BE1318, Brunei Darussalam**

[86] **PCT/CN2019/126780**

[87] **WO 2021/120133**

[51] **C02F 9/10, C02F 1/04, C07C 29/80**

[57] **Provided is a method for treating production wastewater from the preparation of propylene oxide with a co-oxidation method, wherein the production wastewater includes a first portion of wastewater with a peroxide content of 2000 mg/L or more and a second portion of wastewater with a peroxide content of less than 50 mg/L. The treatment method comprises: (1) performing catalytic oxidation on the first portion of wastewater to obtain discharged wastewater; (2) mixing the discharged wastewater with the second portion of wastewater, then rectifying same via a first rectification tower to obtain a first overhead material and primary concentrated wastewater as a**

first tower bottom liquid; rectifying the first tower bottom liquid via a second rectification tower to obtain a second overhead material and secondary concentrated wastewater as a second tower bottom liquid; and subjecting the first overhead material and the second overhead material to oil-water separation via a third rectification tower; (3) subjecting the second tower bottom liquid to an incineration treatment; and (4) subjecting the third tower bottom liquid to a biochemical treatment. The treatment method is applicable to wastewater with a high content of salt and organic substances and a high peroxide content, and can remove peroxides therefrom, improve the biodegradability of the wastewater, and reduce the difficulty and cost of the treatment of the wastewater.



图 1

******

REGISTRAR OF PATENT
BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT RENEWAL APPLICATION

Patent No.:	**BN/N/2014/0115**
Date of Grant:	**16 April, 2013**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Anti-Baff-Anti-Il17 Bispecific Antibodies**

Patent No.:	**BN/N/2016/0080**
Date of Grant:	**13 April, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**THERMTECH HOLDING AS**
Title of Invention:	**Method Of Treating A Material**

Patent No.:	**BN/N/2016/0084**
Date of Grant:	**16 April, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**DAICEL CORPORATION**
Title of Invention:	**Flange Fastening Skill Determination Apparatus And Flange Fastening Skill Determination Program**

Patent No.:	**BN/N/2016/0086**
Date of Grant:	**5 May, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**

Title of Invention: **Imidazo[4,5-C]Quinolin-2-One Compounds And Their Use In Treating Cancer**

Patent No.: **BN/N/2017/0093**

Date of Grant: **3 May, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **ASTRAZENECA AB**

Title of Invention: **Pyrazole Derivatives Useful As 5-Lipoxygenase Activating Protein (Flap) Inhibitors**

Patent No.: **BN/N/2018/0075**

Date of Grant: **7 February, 2017**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **MOLONEY, LINDSAY**
SCOTT, GUY

Title of Invention: **A System And Method For Document Information Authenticity Verification**

Patent No.: **RE/R/2012/0004**

Date of Grant: **29 April, 2011**

Annuity: **11th Year**

Applicant(s) / Proprietor(s): **SUMITOMO METAL INDUSTRIES LTD**
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: **Threaded Joint For Steel Pipes**

Patent No.: **RE/R/2012/0031**

Date of Grant: **2 April, 2009**

Annuity: **13th Year**

Applicant(s) / Proprietor(s): **MERCK SHARP & DOHME CORP.**

Title of Invention: **Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists**

Patent No.: **RE/R/2013/0026**

Date of Grant: **31 March, 2006**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **WYETH LLC**

Title of Invention: **Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition**

Patent No.: **RE/R/2013/0072**

Date of Grant: **16 April, 2008**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **GLAXO GROUP LIMITED**

Title of Invention: **Tricyclic Nitrogen Containing Compounds As Antibacterial Agents**

Patent No.: **RE/R/2013/0076**

Date of Grant: **31 March, 2009**

Annuity: **13th Year**

Applicant(s) / Proprietor(s): **HYDROBALL TECHNICS HOLDINGS PTE LTD**

Title of Invention: **Cleaning System For Cleaning Tubing**

Patent No.: **RE/R/2014/0001**

Date of Grant: **24 May, 2012**

Annuity: **10th Year**

Applicant(s) / Proprietor(s): **UNITED PIPELINES ASIA PACIFIC PTE LIMITED**

Title of Invention: **Austenitic Stainless Steel**

Patent No.:	**RE/R/2014/0013**
Date of Grant:	**4 April, 2008**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Lubricating Composition With An Adaptable Coefficient Of Friction, For A Threded Element Of A Component Of A Tubular Threaded Joint**

Patent No.:	**RE/R/2017/0007**
Date of Grant:	**15 April, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Treating Allergic And Inflammatory Conditions**

Patent No.:	**RE/R/2017/0009**
Date of Grant:	**30 March, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MERIDIAN MEDICAL TECHNOLOGIES, INC.**
Title of Invention:	**Needle Assemblies For Wet/Dry Automatic Injectors**

Patent No.:	**RE/R/2017/0014**
Date of Grant:	**15 April, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**SCYNEXIS. INC.**
Title of Invention:	**Antifungal Agents**

Patent No.:	**RE/R/2017/0017**
Date of Grant:	**15 April, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC**
Title of Invention:	**Extending Lines Through And Preventing Extrusion Of, Seal Elements Of Packer Assemblies**

Patent No.:	**RE/R/2018/0013**
Date of Grant:	**29 March, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**WYETH LLC**
Title of Invention:	**Triazine Compounds As P13 Kinase And Mtor Inhibitors**

Patent No.:	**RE/R/2018/0014**
Date of Grant:	**5 April, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**VERTEX PHARMACEUTICALS INCORPORATED**
Title of Invention:	**Modulators Of Atp-Binding Cassette Transporters**

Patent No.:	**RE/R/2018/0016**
Date of Grant:	**14 April, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**GENENTECH, INC.**
Title of Invention:	**Compositions And Methods Containing Alkylglycosides For Stabilizing Protein-Containing Formulations**

Patent No.:	**RE/R/2018/0017**

Date of Grant:	**20 April, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ABBVIE BAHAMAS LTD.**
Title of Invention:	**Anti-Viral Compounds To Treat Hcv Infection**

Patent No.:	**RP/R/2006/0006**
Date of Grant:	**9 March, 2006**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Novel Form Of S-Omeprazole**

Patent No.:	**RP/R/2007/0030**
Date of Grant:	**30 April, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**SANOFI-AVENTIS**
Title of Invention:	**Polymorphic Clopidogrel Hydrogegensulphate Form**

Patent No.:	**RP/R/2008/0073**
Date of Grant:	**3 November, 2008**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**JANSSEN ALZHEIMER IMMUNOTHERAPY**
Title of Invention:	**Prevention And Treatment Of Amyloidogenic Disease**

Patent No.:	**BN/N/2014/0091**
Date of Grant:	**17 October, 2014**
Annuity:	**9th Year**

Applicant(s) / Proprietor(s): **ELI LILLY AND COMPANY**

Title of Invention: **Pyrazole Compounds As Sglt1 Inhibitors**

Patent No.: **BN/N/2017/0102**

Date of Grant: **7 December, 2017**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **MUN SIONG ENGINEERING LIMITED**

Title of Invention: **Viewing Method After Cleaning Pipeline And Viewing Apparatus Thereof**

Patent No.: **BN/N/2018/0014**

Date of Grant: **7 February, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **ELI LILLY AND COMPANY**

Title of Invention: **Compounds Useful For Inhibiting Ror-Gamma-T**

Patent No.: **BN/N/2018/0101**

Date of Grant: **5 November, 2019**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **BISN TEC LTD**

Title of Invention: **Chemical Heat Sources For Use In Down-Hole Operations**

Patent No.: **Re/R/2012/0012**

Date of Grant: **29 Marach, 2012**

Annuity: **19th Year**

Applicant(s) / Proprietor(s): **Novartis Ag**

Title of Invention: **1 - (3, 4 - Dimethylphenyl) -1 , 5 - Dihydro - Methyl - 5 - Oxo - 4h - Pyrazol - 4 - Ylidene Hydrazine - 2' - Hydroxyl -**

1, 1' - Biphenyl - 3 - Carboxylic Acid

Patent No.:	**RE/R/2012/0012**
Date of Grant:	**29 Marach, 2012**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**NOVARTIS AG**
Title of Invention:	**1 - (3, 4 - Dimethylphenyl) -1 , 5 - Dihydro - Methyl - 5 - Oxo - 4h - Pyrazol - 4 - Ylidene Hydrazine - 2' - Hydroxyl - 1, 1' - Biphenyl - 3 - Carboxylic Acid**

Patent No.:	**RE/R/2013/0061**
Date of Grant:	**29 August, 2011**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**SHOWCASE INC.**
Title of Invention:	**Web Display Program Conversion System, Web Display Program Conversion Method And Program For Converting Web Display Program**

Patent No.:	**RE/R/2014/0028**
Date of Grant:	**15 May, 2014**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**F.HOFFMAN-LA ROCHE AG**
Title of Invention:	**Methods For Improving Pharmacokinetics**

Patent No.:	**RE/R/2015/0031**
Date of Grant:	**30 April, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ACCELERON PHARMA INC.**
Title of Invention:	**ANTI-ACTIVIN A Or B Antibodies And Use Thereof For**

Promoting Bone Growth

Patent No.:	**RE/R/2015/0033**
Date of Grant:	**25 June, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Pyrrolo [2, 3 -D] Pyrimidin Derivatives As Protein Kinase B Inhibitors**

Patent No.:	**RE/R/2016/0014**
Date of Grant:	**17 April, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**THE REGENTS OF THE UNIVERSITY OF CALIFORNIA**
Title of Invention:	**Methods And Systems For Phylogenetic Analysis**

Patent No.:	**RE/R/2016/0015**
Date of Grant:	**26 May, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**BAVARIAN NORDIC A/S**
Title of Invention:	**Use Of A Modified Poxvirus For The Rapid Induction Of Immunity Against A Poxvirus Or Other Infectious Agents**

Patent No.:	**RE/R/2016/0027**
Date of Grant:	**25 April, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Method And System For Treating Water Used For Industrial Purposes**

Patent No.:	**RE/R/2017/0012**
Date of Grant:	**22 March, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Coated Tablet Formulation And Method**

Patent No.:	**RE/R/2017/0024**
Date of Grant:	**16 May, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ONO PHARMACEUTICAL CO., LTD.**
Title of Invention:	**Purinone Derivatve**

Patent No.:	**RE/R/2017/0024**
Date of Grant:	**16 May, 2016**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ONO PHARMACEUTICAL CO., LTD.**
Title of Invention:	**Purinone Derivatve**

Patent No.:	**RE/R/2018/0019**
Date of Grant:	**31 May, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**BAVARIAN NORDIC A/S**
Title of Invention:	**Immediate Protection Against Pathogens Via Mva**

Patent No.:	**RP/R/2005/0023**

Date of Grant: 10 May, 2005

Annuity: 20th Year

Applicant(s) / Proprietor(s): AstraZeneca Ab

Title of Invention: Formulation

Patent No.: RP/R/2006/0031

Date of Grant: 11 November, 2006

Annuity: 16th Year

Applicant(s) / Proprietor(s): CERTIS CISCO SECURITY PTE LTD

Title of Invention: Computer Security Event Management System

---

Patent No.: RP/R/2007/0057

Date of Grant: 22 November, 2007

Annuity: 17th Year

Applicant(s) / Proprietor(s): Arena Pharmaceuticals, Inc.

Title of Invention: 5ht2c Receptor Modulators

Patent No.: RP/R/2008/0003

Date of Grant: 14 January, 2008

Annuity: 16th Year

Applicant(s) / Proprietor(s): Novartis AG

Title of Invention: N-(Substituted Glycyl)-2-Cyanopyrrolidines, Pharmaceutical Compositions Containing Them And Their Use In Inhibiting Dipeptidyl Peptidase -Iv

---

Patent No.: RP/R/2008/0003

Date of Grant: 14 January, 2008

Annuity: 15th Year

Applicant(s) / Proprietor(s):	**NOVARTIS AG**
Title of Invention:	**N-(Substituted Glycyl)-2-Cyanopyrrolidines, Pharmaceutical Compositions Containing Them And Their Use In Inhibiting Dipeptidyl Peptidase -Iv**

Patent No.:	**RP/R/2009/0020**
Date of Grant:	**9 June, 2009**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**CHAMPION TECHNOLOGIES, INC**
Title of Invention:	**Low Dosage Naphthenate Inhibitors**

Patent No.:	**RP/R/2010/0008**
Date of Grant:	**17 April, 2010**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Diaryl Ethers As Opioid Receptor Antagonist**

Patent No.:	**BN/N/2014/0114**
Date of Grant:	**8 December, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**BERTHOLD SICHERT GMBH**
Title of Invention:	**Underground Switch Cabinet For Electric Installation**

Patent No.:	**BN/N/2017/0086**
Date of Grant:	**26 October, 2017**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**

Title of Invention: **Completion System For Gravel Packing With Zonal Isolation**

Patent No.: **BN/N/2018/0105**

Date of Grant: **23 November, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **BISN TEC LTD**

Title of Invention: **Combined Well Plug/Chemical Heater Assemblies For Use In Down-Hole Operations And Associated Heater Cartridges**

Patent No.: **BN/N/2018/0106**

Date of Grant: **23 November, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **BISN TEC LTD**

Title of Invention: **Down-Hole Chemical Heater And Methods Of Operating Such**

Patent No.: **RE/R/2012/0035**

Date of Grant: **27 July, 2012**

Annuity: **11th Year**

Applicant(s) / Proprietor(s): **BOEHRINGER INGELHEIM INTERNATIONAL GMBH**

Title of Invention: **Dpp Iv Inhibitor Formulations**

Patent No.: **RE/R/2013/0007**

Date of Grant: **14 January, 2013**

Annuity: **12th Year**

Applicant(s) / Proprietor(s): **OPULENT ELECTRONICS INTERNATIONAL PTE LTD**

Title of Invention: **Device And Method For Driving Leds**

Patent No.:	**RE/R/2013/0025**
Date of Grant:	**13 March, 2013**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**DEBIOPHARM INTERNATIONAL SA**
Title of Invention:	**Slow Release Pharmaceutical Composition Made Of Microparticles**

Patent No.:	**RE/R/2013/0045**
Date of Grant:	**7 August, 2013**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**PTC THERAPEUTICS, INC.**
Title of Invention:	**Compositions Of An Orally Active 1,2,4-Oxadiazole For Nonsense Mutation Suppression Therapy**

Patent No.:	**RE/R/2013/0045**
Date of Grant:	**6 April, 2006**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**PTC THERAPEUTICS, INC.**
Title of Invention:	**Compositions Of An Orally Active 1,2,4-Oxadiazole For Nonsense Mutation Suppression Therapy**

Patent No.:	**RE/R/2014/0032**
Date of Grant:	**11 June, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**CURIS, INC.**
Title of Invention:	**Fused Amino Pyridine As Hsp90 Inhibitors**

Patent No.:	**RE/R/2014/0032**
Date of Grant:	**11 June, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**CURIS, INC.**
Title of Invention:	**Fused Amino Pyridine As Hsp90 Inhibitors**

Patent No.:	**RE/R/2014/0043**
Date of Grant:	**4 July, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**INDUSTRIAL GALVANIZERS CORPORATION PTY LTD**
Title of Invention:	**Improved Road Barrier**

Patent No.:	**RE/R/2014/0068**
Date of Grant:	**21 July, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ROYALTY PHARMA COLLECTION TRUST**
Title of Invention:	**Treatment Of Type 2 Diabetes With A Combination Of DPIV Inhibitor And Metformin Or Thiazolidinedione**

Patent No.:	**RE/R/2015/0014**
Date of Grant:	**14 May, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**TOTAL S.A.**
Title of Invention:	**Pipe For Transporting A Fluid Containing A Hydrocarbon, And Method For Producing Such A Line**

Patent No.:	**RE/R/2015/0026**

Date of Grant:	**14 May, 2014**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**WYETH LLC**
Title of Invention:	**Treatment Of Imatinib Resistant Leukemia Using 4-Aminoquinoline-3-Carbonitriles**

Patent No.:	**RE/R/2015/0040**
Date of Grant:	**28 May, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ACCELERON PHARMA, INC.**
Title of Invention:	**Variants Derived From Actriib And Uses Therefor**

Patent No.:	**RE/R/2015/0064**
Date of Grant:	**24 June, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**MERUS N.V.**
Title of Invention:	**Antibody Producing Non-Human Mammals**

Patent No.:	**RE/R/2016/0036**
Date of Grant:	**13 May, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**DOLBY INTERNATIONAL AB** **DOLBY LABORATORIES LICENSING CORPORATION**
Title of Invention:	**Audio Decoder And Decoding Method Using Efficient Downmixing**

Patent No.:	**RE/R/2017/0038**
Date of Grant:	**24 May, 2017**

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Tubular Threaded Element Provided With A Dry Protective Coating

---

Patent No.: RE/R/2018/0021

Date of Grant: 25 March, 2008

Annuity: 5th Year

Applicant(s) / Proprietor(s): PFIZER PRODUCTS INC.

Title of Invention: Crystalline Forms Of 6- [2- (Methylcarbamoyl) Phenylsulfanyl] -3-E- [2- (Pyridin-2-Yl) Ethenyl] Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals

---

Patent No.: RP/R/2007/0017

Date of Grant: 28 March, 2007

Annuity: 16th Year

Applicant(s) / Proprietor(s): TWISTER B.V.

Title of Invention: Cyclonic Fluid Separator With Vortex Generator In Inlet Section

---

Patent No.: RP/R/2011/0029

Date of Grant: 15 June, 2011

Annuity: 11th Year

Applicant(s) / Proprietor(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Title of Invention: Uses Of Dpp-Iv Inhibitors

Patent No.: BN/N/2015/0119

Date of Grant:	**5 November, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**WCM OIL & GAS SDN BHD**
Title of Invention:	**Welding Isolation Chamber Habitat System**

Patent No.:	**BN/N/2018/0016**
Date of Grant:	**22 February, 2018**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**NANYANG TECHNOLOGICAL UNIVERSITY** **PROGEN PTE LTD**
Title of Invention:	**Passive Chilled Panel**

Patent No.:	**BN/N/2018/0104**
Date of Grant:	**15 September, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Threaded Connection**

Patent No.:	**BN/N/2019/0013**
Date of Grant:	**21 June, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**AVASURE, LLC**
Title of Invention:	**Video Load Balancing System For A Peer-To-Peer Server Network**

Patent No.:	**RE/R/2012/0006**

Date of Grant: 30 April, 2007

Annuity: 11th Year

Applicant(s) / Proprietor(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Title of Invention: Polymorphs

Patent No.: RE/R/2012/0016

Date of Grant: 14 March, 2012

Annuity: 15th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 2-6-(3-Amino-Piperidin-1-Yl)-3-Methyl-2, 4-Dioxo-3, 4-Dihydro-2h-Pyrimidin-1-Ylmethyl-4-Fluoro-Benzonitrile For Treating Diabetes, Cancer, Autoimmune Disorders And Hiv Infection

---

Patent No.: RE/R/2012/0022

Date of Grant: 24 April, 2012

Annuity: 16th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Dipeptidyl Peptidase Inhibitors For Treating Diabetes

---

Patent No.: RE/R/2012/0060

Date of Grant: 6 December, 2012

Annuity: 17th Year

Applicant(s) / Proprietor(s): PFIZER, INC.

Title of Invention: Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors

---

Patent No.: RE/R/2013/0065

Date of Grant: 11 September, 2013

Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**ARRAY BIOPHARMA, INC.**
Title of Invention:	**8-Substituted Benzoazepines As Toll-Like Receptor Modulators**

Patent No.:	**RE/R/2013/0088**
Date of Grant:	**29 November, 2013**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**PFIZER INC**
Title of Invention:	**Pyrazole-Substituted Aminoheteroaryl Compounds As Protein Kinase Inhibitors**

Patent No.:	**RE/R/2013/0092**
Date of Grant:	**17 December, 2013**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title of Invention:	**Administration Of Dipeptidyl Peptidase Inhibitors**

Patent No.:	**RE/R/2015/0030**
Date of Grant:	**16 July, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**SUGEN, INC.**
Title of Invention:	**Aminoheteroaryl Compounds As Protein Kinase Inhibitors**

Patent No.:	**RE/R/2016/0007**
Date of Grant:	**11 March, 2016**
Annuity:	**7th Year**

Applicant(s) / Proprietor(s): **REGENERON PHARMACEUTICALS, INC.**

Title of Invention: **High Affinity Human Antibodies To Pcsk9**

Patent No.: **RE/R/2016/0011**

Date of Grant: **17 June, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **WYETH LLC**

Title of Invention: **Anti-Tumor Activity Of Temsirolimus In Papillary Renal Cell Cancer**

Patent No.: **RE/R/2017/0039**

Date of Grant: **17 August, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **PFIZER INC.**

Title of Invention: **N1-Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors**

Patent No.: **RE/R/2017/0040**

Date of Grant: **24 August, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **MERIDIAN MEDICAL TECHNOLOGIES, INC**

Title of Invention: **Drug Delivery Device**

Patent No.: **RE/R/2017/0041**

Date of Grant: **24 August, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **IMMUNOGEN, INC.**

Title of Invention: **Folate Receptor 1 Antibodies And Immunoconjugates And Uses Thereof**

Patent No.:	**RE/R/2018/0024**
Date of Grant:	**21 June, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ANACOR PHARMACEUTICALS, INC.**
Title of Invention:	**Benzoxaborole Derivatives For Treating Bacterial Infections**

Patent No.:	**RE/R/2018/0030**
Date of Grant:	**27 October, 2011**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**AMGEN RESEARCH (MUNICH) GMBH**
Title of Invention:	**Means And Methods For Treating Dlblcl**

Patent No.:	**RP/R/2011/0044**
Date of Grant:	**29 October, 2010**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**ASTEX PHARMACEUTICALS, INC.**
Title of Invention:	**Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein**

Patent No.:	**RP/R/2011/0047**
Date of Grant:	**10 November, 2011**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**PFIZER LIMITED**
Title of Invention:	**Carboxamide Derivatives As Muscarinic Receptor Antagonists**

Patent No.:	**BN/N/2016/0005**
Date of Grant:	**22 January, 2016**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**KOURIS, PAUL, STEVEN**
Title of Invention:	**An Assembly For Generating Electricity**

Patent No.:	**BN/N/2017/0082**
Date of Grant:	**9 October, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**CS CONSTRUCTION & GEOTECHNIC PTE LTD**
Title of Invention:	**System And Method For Securing, Moving And Placing A Pile Or Heavy Elongated Object**

Patent No.:	**BN/N/2018/0007**
Date of Grant:	**29 January, 2018**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MEDRX CO. LTD.**
Title of Invention:	**Transdermally Absorptive Composition**

Patent No.:	**RE/R/2013/0033**
Date of Grant:	**18 April, 2013**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP** **MSD ITALIA S.R.L.**
Title of Invention:	**Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors**

Patent No.:	**RE/R/2013/0059**

Date of Grant:	**31 July, 2013**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**PIERRE FABRE MEDICAMENT**
Title of Invention:	**Novel Antibodies Inhibiting C-Met Dimerization, And Uses Thereof**

Patent No.:	**RE/R/2017/0053**
Date of Grant:	**31 October, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**METROL TECHNOLOGY LIMITED**
Title of Invention:	**Casing Valve**

Patent No.:	**RE/R/2017/0054**
Date of Grant:	**4 August, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**METROL TECHNOLOGY LIMITED**
Title of Invention:	**A Well Comprising A Safety Mechanism And Sensors**

Patent No.:	**RE/R/2018/0028**
Date of Grant:	**2 August, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**HOSPIRA, INC.**
Title of Invention:	**Spray Drying Vancomycin**

Patent No.:	**RE/R/2018/0031**
Date of Grant:	**30 August, 2017**
Annuity:	**5th Year**

Applicant(s) / Proprietor(s): PFIZER IRELAND PHARMACEUTICALS

Title of Invention: Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound

---

Patent No.: RP/R/2010/0041

Date of Grant: 27 December, 2010

Annuity: 13th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Pharmaceutical Composition Containing Proton Pump Inhibitors

---

Patent No.: BN/N/2015/0010

Date of Grant: 4 February, 2015

Annuity: 9th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipe

Patent No.: BN/N/2015/0130

Date of Grant: 8 March, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): SAFWAY SERVICES, LLC

Title of Invention: Access Structure Integration Assembly And Integrated Access Systems And Methods Of Using The Same

---

Patent No.: BN/N/2016/0006

Date of Grant: 4 February, 2016

Annuity: 8th Year

Applicant(s) / Proprietor(s):	**CHIYODA CORPORATION**
Title of Invention:	**Hydrogen Supply System And Hydrogen Supply Method**

Patent No.:	**BN/N/2018/0008**
Date of Grant:	**31 July, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**AKESO BIOPHARMA, INC.**
Title of Invention:	**An Anti-Ctla4 Monoclonal Antibody Or Antigen Binding Fragment Thereof, A Pharmaceutical Composition And Use**

Patent No.:	**BN/N/2018/0018**
Date of Grant:	**15 September, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective Modulators Of Ataxia Telangiectasia Mutated (Atm) Kinase For The Treatment Of Cancer**

Patent No.:	**BN/N/2018/0072**
Date of Grant:	**2 February, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**AMGEN RESEARCH (MUNICH) GMBH**
Title of Invention:	**Psma And Cd3 Bispecific T Cell Engaging Antibody Constructs**

Patent No.:	**RE/R/2012/0049**
Date of Grant:	**17 October, 2012**
Annuity:	**16th Year**

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 1 - Heterocyclylsulfonyl, 2 - Aminomethyl, 5 - (Hetero -) Aryl Substituted 1 - H - Pyrrole Derivatives As Acid Secretion Inhibitors

---

Patent No.: RE/R/2012/0061

Date of Grant: 20 December, 2012

Annuity: 11th Year

Applicant(s) / Proprietor(s): HELSINN HEALTHCARE SA

Title of Invention: Liquid Pharmaceutical Formulations Of Palonosetron

---

Patent No.: RE/R/2013/0017

Date of Grant: 18 February, 2013

Annuity: 13th Year

Applicant(s) / Proprietor(s): THOMSON LICENSING

Title of Invention: Method For Representing Animated Menu Buttons

---

Patent No.: RE/R/2013/0081

Date of Grant: 11 November, 2013

Annuity: 10th Year

Applicant(s) / Proprietor(s): HOUSING AND DEVELOPMENT BOARD

Title of Invention: A Plant Tray

Patent No.: RE/R/2013/0090

Date of Grant: 13 December, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Title of Invention: **Treatment For Diabetes In Patients Inappropriate For Metformin Therapy**

Patent No.: **RE/R/2013/0090**

Date of Grant: **13 December, 2013**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **BOEHRINGER INGELHEIM INTERNATIONAL GMBH**

Title of Invention: **Treatment For Diabetes In Patients Inappropriate For Metformin Therapy**

Patent No.: **RE/R/2014/0044**

Date of Grant: **11 July, 2014**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **ONE SMART STAR LIMITED**

Title of Invention: **Communicating With Business Customers**

Patent No.: **RE/R/2014/0055**

Date of Grant: **29 September, 2014**

Annuity: **11th Year**

Applicant(s) / Proprietor(s): **NOVARTIS AG**

Title of Invention: **Combination Of Glycopyrrolate And Beta2 Adrenoceptor Agonists**

Patent No.: **RE/R/2015/0047**

Date of Grant: **31 July, 2014**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **OIL STATES INTERNATIONAL**

Title of Invention: **Two-Element Tandem Flexible Joint**

Patent No.:	**RE/R/2015/0070**
Date of Grant:	**12 February, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ALMIRALL, S.A.**
Title of Invention:	**Inhalation composition containing aclidinium for treatment of chronic obstructive pulmonary disease**

Patent No.:	**RE/R/2016/0026**
Date of Grant:	**19 August, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**GILEAD PHARMASSET LLC**
Title of Invention:	**Antiviral Compounds**

Patent No.:	**RE/R/2017/0020**
Date of Grant:	**10 May, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC. (US)** **JAPAN TOBACCO, INC.**
Title of Invention:	**Methods For Improving The Pharmacokinetics Of Hiv Intergase**

Patent No.:	**RE/R/2017/0026**
Date of Grant:	**30 August, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**GLAXOSMITHKLINE LLC**
Title of Invention:	**Novel Phamaceutical Composition**

Patent No.: RE/R/2017/0037

Date of Grant: 27 July, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): WYETH HOLDINGS LLC

Title of Invention: Calicheamicin Derivative-Carrier Conjugates

---

Patent No.: RE/R/2018/0004

Date of Grant: 31 May, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Pipes

Patent No.: RE/R/2018/0026

Date of Grant: 31 July, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): KUDOS PHARMACEUTICALS LIMITED

Title of Invention: Phthalazinone Derivative

Patent No.: RP/R/2003/0016

Date of Grant: 13 November, 2003

Annuity: 20th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

Title of Invention: Method For Drilling And Completing A Hydrocarbon Production Well

---

Patent No.: RP/R/2005/0002

Date of Grant:	**9 March, 2005**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**JANSSEN PHARMACEUTICA N.V.**
Title of Invention:	**Aqueous Suspensions Of Submicron 9-Hydroxyrisperidone Fatty Acid Esters**

Patent No.:	**RP/R/2005/0002**
Date of Grant:	**9 March, 2005**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**JANSSEN PHARMACEUTICA N.V.**
Title of Invention:	**Aqueous Suspensions Of Submicron 9-Hydroxyrisperidone Fatty Acid Esters**

Patent No.:	**RP/R/2005/0006**
Date of Grant:	**30 April, 2005**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Method For Annular Sealing**

Patent No.:	**RP/R/2007/0028**
Date of Grant:	**23 May, 2007**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**SATOSHI SAWAMURA**
Title of Invention:	**Transparent Silicone Film-Forming Composition And Method For Curing Same**

Patent No.:	**RP/R/2009/0038**

Date of Grant: 18 December, 2009

Annuity: 20th Year

Applicant(s) / Proprietor(s): BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY

Title of Invention: Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors

---

Patent No.: RP/R/2011/0041

Date of Grant: 12 October, 2011

Annuity: 16th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 1-Heterocyclylsulfonyl, 2-Aminomethyl, 5- (Hetero-) Aryl Substituted 1-H-Pyrrole Derivatives As Acid Secretion Inhibitors

---

Patent No.: BN/N/2016/0088

Date of Grant: 21 November, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Coupling For Steel Piping

Patent No.: BN/R/2020/0006

Date of Grant: 29 August, 2020

Annuity: 11th Year

Applicant(s) / Proprietor(s): MEDIMMUNE LIMITED

Title of Invention: Targeted Binding Agents Against B7-H1

Patent No.: BN/N/2016/0033

Date of Grant:	**25 April, 2016**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Glucopyranosyl-Substituted Indole-Urea Derivatives And Their Use As Sglt Inhibitors**

Patent No.:	**RE/R/2015/0062**
Date of Grant:	**4 November, 2015**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**NEWRON PHARMACEUTICALS S.P.A.**
Title of Invention:	**Process For The Production Of 2- [4 - (3- And 2-Flu0r0benzyl0xy) Benzylamin0] Propan Amides**

Patent No.:	**RE/R/2017/0001**
Date of Grant:	**16 January, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ALMIRALL S.A.**
Title of Invention:	**New Cyclohexylamine Derivatives Having Beta2 Adrenergic Agonist And M3 Muscarinic Antagonist Activities**

Patent No.:	**BN/N/2014/0025**
Date of Grant:	**24 March, 2014**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Tubular Threaded Joint Having Improved High Torque Performance**

Patent No.:	**BN/N/2017/0026**
Date of Grant:	**6 April, 2017**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Aurora A Kinase Inhibitor**

Patent No.:	**BN/N/2019/0048**
Date of Grant:	**4 April, 2019**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**MEDIMMUNE LIMITED**
Title of Invention:	**Pyrrolobenzodiazepine Conjugates**

Patent No.:	**RE/R/2012/0056**
Date of Grant:	**5 November, 2012**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**HIGH SEALED AND COUPLED "HSC" FZCO**
Title of Invention:	**An Improved Seal Between Pipes**

Patent No.:	**RE/R/2012/0062**
Date of Grant:	**12 December, 2012**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**ABBOTT LABORATORIES**
Title of Invention:	**Infant Formulas Containing Docosahexaenoic Acid And Lutein**

Patent No.:	**RE/R/2013/0086**
Date of Grant:	**20 November, 2013**

Annuity: 11th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V

Title of Invention: Processes For The Preparation Of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-Dimethylphenyl]Amino]-2-Pyrimidinyl]Amino]Benzonitrile

---

Patent No.: RE/R/2014/0017

Date of Grant: 2 April, 2014

Annuity: 9th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES LTD.
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipes

Patent No.: RE/R/2016/0004

Date of Grant: 15 October, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): PFIZER INC

Title of Invention: Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives

---

Patent No.: RE/R/2016/0043

Date of Grant: 3 November, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): MERIDIAN MEDICAL TECHNOLOGIES, INC.

Title of Invention: Drug Delivery System With A Small Amount Of A Therapeutic Agent

---

Patent No.: RE/R/2017/0050

Date of Grant: 14 October, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): **GENENTECH, INC.**

Title of Invention: **Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof**

Patent No.: **RE/R/2017/0050**

Date of Grant: **14 October, 2016**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **GENENTECH, INC.**

Title of Invention: **Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof**

Patent No.: **RE/R/2017/0052**

Date of Grant: **13 October, 2017**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **EISAI R&D MANAGEMENT CO., LTD.**

Title of Invention: **Compositions And Methods For Treating Inflammatory Disorders**

Patent No.: **RE/R/2017/0056**

Date of Grant: **30 October, 2017**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **IMMUNOGEN, INC.**

Title of Invention: **Cross-Linkers And Their Uses**

Patent No.: **RE/R/2018/0007**

Date of Grant: **22 February, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **NIPPON SHINYAKU CO., LTD.**

Title of Invention:	**Crystals**

Patent No.:	**RE/R/2018/0015**
Date of Grant:	**28 March, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**THE EUROPEAN UNION, REPRESENTED BY THE EUROPEAN COMMISSION**
Title of Invention:	**Tsunami Warning System And Method For Providing Tsunami Warnings**

Patent No.:	**RE/R/2018/0034**
Date of Grant:	**13 October, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**TENSA ENGINEERING SDN. BHD.**
Title of Invention:	**Apparatus And Method For Manufacturing A Spiral Tank**

Patent No.:	**BN/N/2017/0019**
Date of Grant:	**21 March, 2017**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Treatment Of Androgen Deprivation Therapy Associated Symptoms**

Patent No.:	**BN/N/2017/0019**
Date of Grant:	**21 March, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ELI LILLY AND COMPANY**
Title of Invention:	**Treatment Of Androgen Deprivation Therapy Associated**

Symptoms

Patent No.: **BN/N/2017/0070**

Date of Grant: **29 August, 2017**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **HERNÁNDEZ MIRAMONTES, JORGE ANTONIO**

Title of Invention: **Mixture Of Carboxylic Acids For Treating Patients With Kidney Failure**

Patent No.: **RE/R/2013/0062**

Date of Grant: **2 September, 2009**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **PURDUE PHARMA L.P.**

Title of Invention: **Tamper Resistent Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic**

Patent No.: **RE/R/2016/0040**

Date of Grant: **16 September, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **ACCELERON PHARMA INC.**

Title of Invention: **Activin-Actrii Antagonists And Uses For Increasing Red Blood Cell Levels**

Patent No.: **RE/R/2017/0048**

Date of Grant: **25 September, 2017**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **MSD K.K.**

Title of Invention: **Dihydropyrazolopyrimidinone Derivative**

Patent No.:	**RE/R/2018/0033**
Date of Grant:	**7 September, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ABBVIE DEUTSCHLAND GMBH & CO KG ABBVIE INC.**
Title of Invention:	**Monoclonal Antibodies And Uses Thereof**

Patent No.:	**RP/R/2004/0001**
Date of Grant:	**8 April, 2004**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**MERCK CANADA INC.**
Title of Invention:	**Substituted Pyridines As Selective Cyclooxygenase-2 Inhibitors**

Patent No.:	**RP/R/2007/0060**
Date of Grant:	**28 November, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor**

Patent No.:	**RP/R/2011/0008**
Date of Grant:	**2 February, 2011**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**GLAXO GROUP LIMITED**
Title of Invention:	**Phenethanolamine Derivatives For Treatment Of Respiratory Diseases**

Patent No.:	**BN/N/2015/0017**
Date of Grant:	**11 March, 2015**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Single Trip Multi-Zone Completion Systems And Methods**

Patent No.:	**BN/N/2015/0021**
Date of Grant:	**16 March, 2015**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Tubing Conveyed Multiple Zone Integrated Intelligent Well Completion**

Patent No.:	**BN/N/2015/0027**
Date of Grant:	**23 March, 2015**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Completion Assembly And Methods For Use Thereof**

Patent No.:	**BN/N/2015/0030**
Date of Grant:	**24 March, 2015**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Single Trip Multi-Zone Completion Systems And Methods**

Patent No.:	**RE/R/2013/0067**
Date of Grant:	**19 September, 2013**

Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**PURDUE PHARMA L.P.**
Title of Invention:	**Substituted-Quinoxaline-Type-Piperidine Compounds And The Uses Thereof**

Patent No.:	**RE/R/2014/0005**
Date of Grant:	**8 January, 2014**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title of Invention:	**Solid Preparation**

Patent No.:	**RE/R/2016/0049**
Date of Grant:	**22 December, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**JANSSEN SCIENCES IRELAND UC**
Title of Invention:	**Aqueous Suspensions Of Tmc278**

Patent No.:	**RE/R/2017/0019**
Date of Grant:	**17 April, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MSD K.K.**
Title of Invention:	**Bicycloaniline Derivative**

Patent No.:	**RE/R/2018/0012**
Date of Grant:	**22 March, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**FLEXSTEEL PIPELINE TECHNOLOGIES, INC.**

Title of Invention:	**Flexible Pipe Joint**

Patent No.:	**RE/R/2018/0035**
Date of Grant:	**18 October, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**N-Acylsulfonamide Apoptosis Promoters**

Patent No.:	**RP/R/2009/0021**
Date of Grant:	**08 October, 2008**
Annuity:	**14th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Borehole Imaging**

Patent No.:	**RP/R/2009/0037**
Date of Grant:	**07 October, 2009**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V**
Title of Invention:	**Method For Optimising The Production Of A Cluster Of Wells**

Patent No.:	**BN/N/2016/0028**
Date of Grant:	**10 October, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**BERLIN-CHEMIE AG**
Title of Invention:	**Conjugated Antibodies Against Ly75 For The Treatment Of Cancer**

Patent No.:	**BN/N/2017/0035**
Date of Grant:	**09 November, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**MEDIMMUNE LIMITED**
Title of Invention:	**Binding Molecules Specific For Cd73 And Uses Thereof**

Patent No.:	**BN/N/2017/0044**
Date of Grant:	**30 November, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**1-[2-(Aminomethyl)Benzyl]-2-Thioxo-1,2,3,5-Tetrahydro-4h-Pyrrolo[3,2-D]Pyrimidin-4-Ones As Inhibitors Of Myeloperoxidase**

Patent No.:	**BN/N/2018/0055**
Date of Grant:	**14 December, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Isoindole Compounds**

Patent No.:	**BN/N/2019/0052**
Date of Grant:	**10 October, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ARRAY BIOPHARMA INC.**
Title of Invention:	**Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors**

Patent No.:	**RE/R/2012/0029**
Date of Grant:	**30 November, 2009**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**PEAK WELL SYSTEMS PTY LTD**
Title of Invention:	**A Retrievable Downhole Tool And Running Tool**

Patent No.:	**RE/R/2013/0020**
Date of Grant:	**22 December, 2004**
Annuity:	**19th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Maleate Salts Of A Quinazoline Derivative Useful As An Antiangiogenic Agent**

Patent No.:	**RE/R/2014/0067**
Date of Grant:	**20 November, 2013**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Pyrimidine Sulphonamide Derivatives As Chemokine Receptor Modulators**

Patent No.:	**RE/R/2015/0066**
Date of Grant:	**31 December, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**ARDEA BIOSCIENCES, INC.**
Title of Invention:	**Thioacetate Compounds,Compositions And Methods Of Use**

Patent No.:	**RE/R/2015/0069**
Date of Grant:	**23 December, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**GILEAD BIOLOGICS, INC.**
Title of Invention:	**Antibodies That Bind To Lysyl Oxidase-Like 2(Loxl2) And Methods Of Use Therefor**

Patent No.:	**RE/R/2016/0017**
Date of Grant:	**29 September, 2011**
Annuity:	**11th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB** **NEKTAR THERAPEUTICS**
Title of Invention:	**Crystalline Naloxol-Peg Conjugate**

Patent No.:	**RE/R/2017/0008**
Date of Grant:	**07 December, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Method Of Preparing An Inhibitor Of Cytochrome P450 Monooxygenase, And Intermediates Involved**

Patent No.:	**RE/R/2017/0058**
Date of Grant:	**15 November, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**PETROLIAM NASIONAL BERHAD (PETRONAS)**
Title of Invention:	**Water Curable Resin Formulations**

Patent No.: RE/R/2018/0029

Date of Grant: 7 December, 2009

Annuity: 13th Year

Applicant(s) / Proprietor(s): GILEAD SCIENCES, INC.

Title of Invention: Modulators Of Toll-Like Receptors

Patent No.: RP/R/2005/0001

Date of Grant: 31 October, 2002

Annuity: 20th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.

Title of Invention: Aqueous Risperidone Formulations

Patent No.: RP/R/2006/0014

Date of Grant: 01 October, 2003

Annuity: 19th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Crystal Modification Of A N-Phenyl-2-Pyrimidineamine Derivative, Processes For Its Manufacture And Its Use

---

Patent No.: RP/R/2009/0017

Date of Grant: 31 October, 2007

Annuity: 15th Year

Applicant(s) / Proprietor(s): JANSSEN ALZHEIMER IMMUNOTHERAPY

Title of Invention: Prevention And Treatment Of Amyloidogenic Disease

---

Patent No.: RP/R/2009/0039

Date of Grant: 17 December, 2008

Annuity: 14th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Method For Expanding A Steel Tubing And Well With Such As Tubing

---

Patent No.: RP/R/2010/0012

Date of Grant: 19 November, 2008

Annuity: 14th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Inhibitors Of Tyrosine Kinases

Patent No.: RP/R/2011/0048

Date of Grant: 05 October, 2011

Annuity: 11th Year

Applicant(s) / Proprietor(s): MERCK SHARP AND DOHME CORP.

Title of Invention: Polycyclic Indazole Derivatives That Are Erk Inhibitors

---

Patent No.: BN/N/2014/0104

Date of Grant: 24 June, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL & GAS FRANCE

Title of Invention: Electroplating Device

Patent No.: BN/N/2016/0085

Date of Grant: 16 June, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL & GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipes

Patent No.: BN/N/2018/0068

Date of Grant: 25 January, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): AMGEN INC
AMGEN RESEARCH (MUNICH) GMBH

Title of Invention: Pharmaceutical Composition Comprising Bispecific Antibody Constructs

---

Patent No.: BN/N/2018/0098

Date of Grant: 02 May, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): FOURTH MILITARY MEDICAL UNIVERSITY

Title of Invention: Humanized Anti-Basigin Antibodies And The Use Thereof

---

Patent No.: RE/R/2014/0069

Date of Grant: 14 June 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.

Title of Invention: Fumarate Salt Of (Alpha S, Beta R)-6- Bro,O-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol

---

Patent No.: RE/R/2014/0069

Date of Grant: 14 June 2013

Annuity: 8th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.

Title of Invention: Fumarate Salt Of (Alpha S, Beta R)-6- Bro,O-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol

---

Patent No.: RE/R/2015/0032

Date of Grant: 21 May, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): MERIDIAN MEDICAL TECHNOLOGIES

Title of Invention: Automatic Injector

Patent No.: RE/R/2016/0010

Date of Grant: 15 June, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES LTD.
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipes

Patent No.: RE/R/2016/0019

Date of Grant: 07 July, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): THERACOS SUB, LLC

Title of Invention: Crystalline Form Of Benzylbenzene Sglt2 Inhibitor

---

Patent No.: RE/R/2017/0010

Date of Grant: 15 June, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES, LTD
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Photocurable Composition Suitable For Rust Prevention Of A Threaded Joint For Steel Pipes

---

Patent No.: BN/N/2016/0004

Date of Grant: 01 August, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): LIQWD, INC.

Title of Invention: Methods For Fixing Hair And Skin

Patent No.: BN/N/2017/0002

Date of Grant: 24 July, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: [1,2,4] Triazolo [4,3-B] Pyridazines For Use In The Treatment Of Proliferative Diseases

---

Patent No.: RE/R/2016/0020

Date of Grant: 22 June, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): REGENERON PHARMACEUTICALS, INC

Title of Invention: Stabilized Formulations Containing Anti-Ngf Antibodies

---

Patent No.: RE/R/2016/0024

Date of Grant: 08 July, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): HUTCHISON MEDIPHARMA LIMITED

Title of Invention: Certain Triazolopyrazines, Compositions Thereof And Methods Of Use Therefor

---

Patent No.: RE/R/2017/0021

Date of Grant: 06 July, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): PEARL THERAPEUTICS, INC.

Title of Invention: Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems

---

Patent No.: RE/R/2017/0022

Date of Grant: 06 July, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): PEARL THERAPEUTICS, INC.

Title of Invention: Respiratory Delivery Of Active Agents

Patent No.: RE/R/2017/0023

Date of Grant: 06 July, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): PEARL THERAPEUTICS, INC.

Title of Invention: Compositions For Pulmonary Delivery Of Long-Acting Muscarinic Antagonists And Long-Acting B2 Adrenergic Receptor Agonists And Associated Methods And Systems

---

Patent No.: RE/R/2017/0027

Date of Grant: 15 June, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES, LTD** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Threaded Connection Comprising At Least One Threaded Element With An End Lip For A Metal Tube**

Patent No.:	**RE/R/2017/0031**
Date of Grant:	**20 July, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**KUDOS PHARMACEUTICALS LIMITED**
Title of Invention:	**Pharmaceutical Formulation 514**

Patent No.:	**RE/R/2018/0006**
Date of Grant:	**14 April, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PURDUE PHARMA L.P.**
Title of Invention:	**Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic**

Patent No.:	**RE/R/2018/0010**
Date of Grant:	**01 March, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**PHARMACIA & UPJOHN COMPANY LLC**
Title of Invention:	**Processes For The Preparation Of Crystals Including A Malic Acid Salt Of N-[2-(Diethylamino)Ethyl]-5-[(5-Fluoro-1,2-Dihydro-2-Oxo-3h-Indole-3-Ylidene)Methyl]-2,4-Dimethyl-1h-Pyrrole-3-Carboxamide.**

Patent No.:	**RE/R/2018/0018**
Date of Grant:	**14 July, 2017**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **MITSUBISHI GAS CHEMICAL COMPANY, INC.**

Title of Invention: **Methanol Synthesis Catalyst**

Patent No.: **RP/R/2007/0017**

Date of Grant: **26 July, 2006**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **TWISTER B.V.**

Title of Invention: **Cyclonic Fluid Separator With Vortex Generator In Inlet Section**

Patent No.: **RP/R/2008/0024**

Date of Grant: **11 July, 2007**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **BAVARIAN NORDIC A/S**

Title of Invention: **Modified Vaccinia Virus Ankara For The Vaccination Of Neonates**

Patent No.: **RP/R/2008/0024**

Date of Grant: **11 July, 2007**

Annuity: **14th Year**

Applicant(s) / Proprietor(s): **BAVARIAN NORDIC A/S**

Title of Invention: **Modified Vaccinia Virus Ankara For The Vaccination Of Neonates**

Patent No.: **RP/R/2009/0035**

Date of Grant: **23 June 2000**

Annuity: **23rd Year**

Applicant(s) / Proprietor(s): **GENENTECH, INC.**

Title of Invention: **Humanized Anti-Erbb2 Antibodies And Treatment With Anti-Erbb2 Antibodies**

Patent No.: **RP/R/2010/0009**

Date of Grant: **30 April, 2009**

Annuity: **13th Year**

Applicant(s) / Proprietor(s): **KHOO TIAN AND O-STABLE PANEL SDN. BHD.**

Title of Invention: **Vertical Construction Joints**

Patent No.: **RP/R/2011/0025**

Date of Grant: **30 July, 2010**

Annuity: **12th Year**

Applicant(s) / Proprietor(s): **SUMITOMO METAL INDUSTRIES, LTD**
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: **Lubricating Coating Composition Suitable For Lubrication Of A Threaded Joint**

Patent No.: **BN/N/2015/0004**

Date of Grant: **07 August, 2013**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V**

Title of Invention: **Process For Producing And Separating Oil**

Patent No.: **RE/R/2015/0034**

Date of Grant: **13 August, 2014**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **BIOGEN MA INC.**

Title of Invention: **Heterocyclic Sulfonamides, Uses And Pharmaceutical Compositions Thereof**

Patent No.: **RE/R/2015/0045**

Date of Grant: **13 August, 2014**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **ASTRAZENECA AB**

Title of Invention: **Morpholino Pyrimidines And Their Use In Therapy**

Patent No.: **RE/R/2016/0029**

Date of Grant: **07 July, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **SKYONIC CORPORATION**

Title of Invention: **Carbon Dioxide Sequestrations Involving Two-Salt-Based Thermolytic Processes**

Patent No.: **RE/R/2016/0039**

Date of Grant: **27 July, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **NOVARTIS AG**

Title of Invention: **Treatment Of Solid Kidney Tumours With A Rapamycin Derivative**

Patent No.: **RE/R/2017/0046**

Date of Grant: **09 August, 2017**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **MEDIMMUNE LIMITED**

Title of Invention: **Targeted Binding Agents Against B7-H1**

Patent No.: **RE/R/2018/0027**

Date of Grant: **31 July, 2017**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **AMGEN K-A, INC.**

Title of Invention: **Lyophilized Therapeutic Peptibody Formulations**

Patent No.: **RE/R/2012/0040**

Date of Grant: **27 January, 2006**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **RONALD NEVILLE LANGFORD**

Title of Invention: **Authenticating Images Identified By A Software Application**

Patent No.: **RP/R/2004/0028**

Date of Grant: **27 August, 2003**

Annuity: **19th Year**

Applicant(s) / Proprietor(s): **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**

Title of Invention: **Method For Transporting And Installing An Expandable Steel Tubular**

Patent No.: **RP/R/2011/0051**

Date of Grant: **24 August, 2011**

Annuity: **11th Year**

Applicant(s) / Proprietor(s): **SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**

Title of Invention: **Marine Time Lapse Seismic Surveying**

Patent No.: **BN/N/2017/0080**

Date of Grant: **30 June, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **HALLIBURTON ENERGY SERVICES, INC**

Title of Invention: **Outflow Control Device For Creating A Packer**

Patent No.: **BN/N/2017/0104**

Date of Grant: **01 July, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **AUDION THERAPEUTICS**
ELI LILLY AND COMPANY

Title of Invention: **Notch Pathway Signaling Inhibitor Compounds**

Patent No.: **RE/R/2013/0091**

Date of Grant: **12 July, 2002**

Annuity: **20th Year**

Applicant(s) / Proprietor(s): **DOLBY LABORATORIES LICENSING CORPORATION**

Title of Invention: **Method And System For Improving Compressed Image Chroma Information**

Patent No.: **RE/R/2014/0011**

Date of Grant: **28 June, 2013**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **SINGAPORE AIRLINES LIMITED**

Title of Invention: **Aircraft Seating And Seating Arrangements**

Patent No.:	**RE/R/2014/0020**
Date of Grant:	**28 June, 2013**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**INCYTE CORPORATION**
Title of Invention:	**Azetidine And Cyclobutane Derivatives As Jak Inihibitors**

Patent No.:	**RE/R/2015/0023**
Date of Grant:	**31 July, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Treatment Fluids Comprising Relative Permeability Modifiers And Methods Of Use**

Patent No.:	**RE/R/2015/0023**
Date of Grant:	**31 July, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Treatment Fluids Comprising Relative Permeability Modifiers And Methods Of Use**

Patent No.:	**RE/R/2015/0054**
Date of Grant:	**17 June, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Modulators Of Pharmacokinetic Properties Of Therapeutics**

Patent No.:	**RE/R/2016/0012**
Date of Grant:	**08 July, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**WYETH HOLDINGS LLC**
Title of Invention:	**Calicheamicin Derivative-Carrier Conjugates**

Patent No.:	**RE/R/2016/0034**
Date of Grant:	**08 July., 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**ESTEVE PHARMACEUTICALS, S.A.**
Title of Invention:	**Pharmaceutical Compositions Of Co-Crystals Of Tramadol And Coxibs**

Patent No.:	**RE/R/2017/0015**
Date of Grant:	**6 July, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.**
Title of Invention:	**Modulators Of Pharmacokinetic Properties Of Therapeutics**

Patent No.:	**RE/R/2017/0030**
Date of Grant:	**08 July, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**GILEAD SCIENCES, INC.** **JAPAN TOBACCO, INC.**
Title of Invention:	**Methods For Improving The Pharmacokinetics Of Hiv Intergrase Inhibitors**

Patent No.: RE/R/2017/0060

Date of Grant: 28 June, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): BAKER HUGHES INCORPORATED

Title of Invention: Method Of Measuring Multi-Phase Fluid Flow Downhole

---

Patent No.: RE/R/2018/0023

Date of Grant: 30 June, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): MATSUMOTO SYSTEM ENGINEERING CO., LTD.

Title of Invention: Grapple Bucket Apparatus

Patent No.: RP/R/2008/0067

Date of Grant: 29 June, 2007

Annuity: 15th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES LTD
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: A Premium Threaded Turbular Connection Comprising At Least One Threaded Element With An End Lip

---

Patent No.: BN/N/2016/0020

Date of Grant: 14 November, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Gravel Packing Apparatus Having Optimized Fluid Handling

---

Patent No.: BN/N/2016/0045

Date of Grant:	**12 November, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Suctioning Device For Large Artificial Water Bodies**

Patent No.:	**BN/N/2019/0085**
Date of Grant:	**21 February, 2018**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Threaded Connection For Oil Well**

Patent No.:	**RE/R/2013/0087**
Date of Grant:	**15 November, 2012**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**OXFORD BIODYNAMICS LIMITED**
Title of Invention:	**Methods Of Detecting Long Range Chromosomal Interactions**

Patent No.:	**RE/R/2015/0046**
Date of Grant:	**05 November, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**TOTAL S.A.**
Title of Invention:	**Heating Device For A Device For Transporting A Fluid Containing A Hydrocarbon**

Patent No.:	**RE/R/2015/0051**

Date of Grant: 19 November, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): WYETH LLC

Title of Invention: Processes For The Convergent Synthesis Of Calicheamicin Derivatives

---

Patent No.: RE/R/2016/0044

Date of Grant: 19 November, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY

Title of Invention: Anti-N3pglu Amyloid Beta Peptide Antibodies And Uses Thereof

---

Patent No.: RP/R/2007/0045

Date of Grant: 30 April, 2007

Annuity: 16th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Substituted 3,5-Diphenyl -1,2,4-Triazoles And Their Use As Pharmaceutical Metal Chelators

---

Patent No.: RP/R/2011/0009

Date of Grant: 13 November, 2006

Annuity: 16th Year

Applicant(s) / Proprietor(s): ERKE ERKE ARASTIRMALARI VE MUHENDISLIK A.S.

Title of Invention: Gyroscopic Apparatus

Patent No.: BN/N/2014/0075

Date of Grant: 05 February, 2013

Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**INNOVATA BIOMED LIMITED**
Title of Invention:	**Improvements Relating To Medicament Delivery Devices**

Patent No.:	**BN/N/2016/0043**
Date of Grant:	**18 June, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**System And Method For Maintaining Water Quality In Large Water Bodies**

Patent No.:	**BN/N/2017/0065**
Date of Grant:	**28 July, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**SIP SOLUTIONS SDN BHD**
Title of Invention:	**A Floating Unit And A Method Of Stabilizing The Floating Unit**

Patent No.:	**RE/R/2013/0034**
Date of Grant:	**28 January, 2004**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**TAKEDA PHARMACEUTICAL COMPANY LIMITED**
Title of Invention:	**Thienopyrimidine Compounds And Use Thereof**

Patent No.:	**RE/R/2016/0037**
Date of Grant:	**27 January, 2016**
Annuity:	**6th Year**

Applicant(s) / Proprietor(s): **EISAI R&D MANANAGEMENT CO., LTD.**

Title of Invention: **Quinoline derivative-containing pharmaceutical composition**

Patent No.: **RP/R/2007/0020**

Date of Grant: **21 March, 2007**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **TWISTER B.V.**

Title of Invention: **Multistage Fluid Separation Assembly And Method**

Patent No.: **BN/N/2017/0063**

Date of Grant: **12 January, 2016**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **TMA CAPITAL AUSTRALIA PTY LTD**

Title of Invention: **System, Method And Computer Program For An Access Control System**

Patent No.: **RE/R/2014/0004**

Date of Grant: **10 September, 2007**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **MEBIOL INC.**

Title of Invention: **Plant Cultivation System**

Patent No.: **RE/R/2016/0028**

Date of Grant: **15 December, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **SUMITOMO METAL INDUSTRIES, LTD.**

	VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	**Threaded Joint For Pipes Having A Lubricating Coating**

Patent No.:	**RE/R/2017/0061**
Date of Grant:	**28 December, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**VERTEX PHARMACEUTICALS INCORPORATED**
Title of Invention:	**Heterocyclic Modulators Of Atp-Binding Cassette Transporters**

Patent No.:	**RP/R/2008/0023**
Date of Grant:	**28 December, 2005**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**BAVARIAN NORDIC A/S**
Title of Invention:	**Modified Vaccinia Ankara Virus Variant**

Patent No.:	**RP/R/2008/0043**
Date of Grant:	**30 December, 2005**
Annuity:	**17th Year**
Applicant(s) / Proprietor(s):	**JANSSEN PHARMACEUTICA N.V.**
Title of Invention:	**Hiv Replication Inhibiting Pyrimidines**

Patent No.:	**RP/R/2009/0015**
Date of Grant:	**31 December, 2007**
Annuity:	**15th Year**
Applicant(s) / Proprietor(s):	**JANSSEN ALZHEIMER IMMUNOTHERAPY**
Title of Invention:	**Prevention And Treatment Of Amyloidogenic Disease**

Patent No.:	**RP/R/2011/0011**
Date of Grant:	**19 January, 2010**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA**
Title of Invention:	**Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit**

Patent No.:	**RP/R/2011/0015**
Date of Grant:	**19 January, 2010**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA**
Title of Invention:	**Coding Method, Decoding Method, Coding Apparatus, Decoding Apparatus, Program, And Integrated Circuit**

Patent No.:	**RE/R/2018/0005**
Date of Grant:	**20 November, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ASTEX THERAPEUTICS LIMITED**
Title of Invention:	**Pyrazolyl Quinoxaline Kinase Inhibitors**

Patent No.:	**BN/N/2016/0026**
Date of Grant:	**09 February, 2015**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**OPULENT ELECTRONICS INTERNATIONAL PTE LTD**
Title of Invention:	**Device And Method For Providing Regulated Current To An Electrical Load**

Patent No.:	**RE/R/2017/0003**
Date of Grant:	**03 February, 2016**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**MERIDIAN MEDICAL TECHNOLOGIES, INC.**
Title of Invention:	**Automatic Injector**

Patent No.:	**RE/R/2017/0042**
Date of Grant:	**15 February, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**ENVIRORESOLUTIONS INC.**
Title of Invention:	**Gas Scrubber Apparatus And Method**

Patent No.:	**RE/R/2017/0042**
Date of Grant:	**15 February, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**ENVIRORESOLUTIONS INC.**
Title of Invention:	**Gas Scrubber Apparatus And Method**

Patent No.:	**RP/R/2006/0010**
Date of Grant:	**22 February, 2006**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**MSD ITALIA S.R.L.**
Title of Invention:	**N-Substituted Hydroxtpyrimidinone Carboxamide Inhibitors Of Hiv Integrase**

Patent No.: BN/N/2014/0084

Date of Grant: 14 March, 2013

Annuity: 9th Year

Applicant(s) / Proprietor(s): PURAPIPE HOLDING LTD.

Title of Invention: Multilayer Pipeline In A Polymer Material, Device For Manufacture Of The Multilayer Pipeline And A Method For Manufacturing The Multilayer Pipeline

---

Patent No.: RE/R/2012/0055

Date of Grant: 13 March, 2003

Annuity: 19th Year

Applicant(s) / Proprietor(s): ARRAY BIOPHARMA, INC
ASTRAZENECA AB

Title of Invention: N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors

---

Patent No.: RE/R/2015/0017

Date of Grant: 12 March, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): WYETH HOLDINGS LLC

Title of Invention: Substituted 3-Cyanoquinolines As Protein Tyrosine Kinases Inhibitors

---

Patent No.: RE/R/2015/0024

Date of Grant: 13 April, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): HELSINN HEALTHCARE SA

Title of Invention: Compositions For Treating Centrally Mediated Nausea And Vomiting

---

Patent No.: **RE/R/2015/0055**

Date of Grant: **10 December, 2014**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **PFIZER INC.**

Title of Invention: **Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives**

Patent No.: **RE/R/2016/0002**

Date of Grant: **11 March, 2015**

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **MERCK CANADA INC.**

Title of Invention: **Non-Necleoside Reverse Transcriptase Inhibitors**

Patent No.: **RE/R/2013/0041**

Date of Grant: **18 December, 2007**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Title of Invention: **Mapk/Erk Kinase Inhibitors**

Patent No.: **RP/R/2011/0045**

Date of Grant: **21 December, 2006**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Title of Invention: **Metastin Derivatives And Use Thereof**

Patent No.: **BN/N/2014/0046**

Date of Grant: **28 August, 2012**

Annuity: 10th Year

Applicant(s) / Proprietor(s): CCP TECHNOLOGY GMBH

Title of Invention: Process And System For Conversion Of Carbon Dioxide To Carbon Monoxide

---

Patent No.: BN/N/2014/0048

Date of Grant: 20 December, 2012

Annuity: 10th Year

Applicant(s) / Proprietor(s): CCP TECHNOLOGY GMBH

Title of Invention: Process And System For Generating Synthesis Gas

---

Patent No.: RE/R/2013/0023

Date of Grant: 22 December, 2006

Annuity: 16th Year

Applicant(s) / Proprietor(s): ARIAD PHARMACEUTICALS, INC.

Title of Invention: Bicyclic Heteroaryl Compounds

Patent No.: RE/R/2016/0046

Date of Grant: 25 November, 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: ActRII Receptor Polypeptides

Patent No.: RE/R/2016/0046

Date of Grant: 25 November, 2015

Annuity: 6th Year

Applicant(s) / Proprietor(s): **ACCELERON PHARMA INC.**

Title of Invention: **ActRII Receptor Polypeptides**

Patent No.: **RE/R/2017/0061**

Date of Grant: **28 December, 2016**

Annuity: **6th Year**

Applicant(s) / Proprietor(s): **VERTEX PHARMACEUTICALS INCORPORATED**

Title of Invention: **Heterocyclic Modulators Of Atp-Binding Cassette Transporters**

Patent No.: **RP/R/2008/0072**

Date of Grant: **21 December, 2004**

Annuity: **18th Year**

Applicant(s) / Proprietor(s): **TAKEDA PHARMACEUTICAL COMPANY LIMITED**

Title of Invention: **Dipeptidyl Peptidase Inhibitors**

Patent No.: **BN/N/2014/0001**

Date of Grant: **19 December, 2012**

Annuity: **10th Year**

Applicant(s) / Proprietor(s): **CRYSTAL LAGOONS (CURACAO) B.V.**

Title of Invention: **Localised Disinfection System For Large Water Bodies**

Patent No.: **BN/N/2015/0079**

Date of Grant: **08 January, 2014**

Annuity: **9th Year**

Applicant(s) / Proprietor(s): **CHANNELL COMMERCIAL CORPORATION**

Title of Invention: **Grade Level Enclosure Conversion Assembly**

Patent No.:	**BN/N/2016/0043**
Date of Grant:	**29 December, 2014**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**System And Method For Maintaining Water Quality In Large Water Bodies**

Patent No.:	**BN/N/2016/0070**
Date of Grant:	**03 March, 2015**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**CHUA, BOON PEN**
Title of Invention:	**A Method Of Priming A Drainage Apparatus For Siphoning Liquid, And A Drainage Apparatus**

Patent No.:	**BN/N/2018/0084**
Date of Grant:	**30 March, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**UMDASCH GROUP NEWCON GMBH**
Title of Invention:	**Formwork Device**

Patent No.:	**RE/R/2017/0011**
Date of Grant:	**26 February, 2016**
Annuity:	**7th Year**
Applicant(s) / Proprietor(s):	**TAKEDA VACCINES, INC.**
Title of Invention:	**Methods And Compositions For Live Attenuated Viruses**

Patent No.:	**RE/R/2019/0002**
Date of Grant:	**26 January, 2018**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**AMGEN INC.**
Title of Invention:	**Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)**

Patent No.:	**RP/R/2003/0031**
Date of Grant:	**12 February, 2003**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Foldable Tube**

Patent No.:	**RP/R/2006/0021**
Date of Grant:	**02 February, 2005**
Annuity:	**18th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**New Formulation For Inhalation Having A Poured Bulk Density Of 0.28 To 0.38 G/Ml, A Process For Preparing The Formulation And The Use Thereof**

Patent No.:	**RP/R/2009/0028**
Date of Grant:	**7 February, 2007**
Annuity:	**16th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**C-Aryl Glucoside Sglt2 Inhibitors And Method**

Patent No.:	**BN/N/2016/0029**
Date of Grant:	**23 January, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Testable Isolation Packer**

Patent No.:	**BN/N/2016/0044**
Date of Grant:	**13 January, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Dual Isolation Well Assembly**

Patent No.:	**BN/N/2017/0039**
Date of Grant:	**13 January, 2015**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Downhole Pressure Maintenance System Using A Controller**

Patent No.:	**BN/N/2017/0043**
Date of Grant:	**13 January, 2015**
Annuity:	**8th Year**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Mechanical Downhole Pressure Maintenance System**

Patent No.:	**BN/N/2019/0055**

Date of Grant: 30 October, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

Title of Invention: Method For Sealing Cavities In Or Adjacent To A Cured Cement Sheath Surrounding A Well Casing

---

Patent No.: RE/R/2012/0038

Date of Grant: 11 January, 2012

Annuity: 11th Year

Applicant(s) / Proprietor(s): VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Method For Pressure Testing A Threaded Component

---

Patent No.: RE/R/2013/0034

Date of Grant: 28 January, 2004

Annuity: 19th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Thienopyrimidine Compounds And Use Thereof

---

Patent No.: RE/R/2015/0050

Date of Grant: 07 January, 2015

Annuity: 8th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Beta-Lactamase Inhibitors

Patent No.: RE/R/2016/0037

Date of Grant: 27 January, 2016

Annuity: **7th Year**

Applicant(s) / Proprietor(s): **EISAI R&D MANANAGEMENT CO., LTD.**

Title of Invention: **Quinoline derivative-containing pharmaceutical composition**

Patent No.: **RE/R/2018/0020**

Date of Grant: **11 January, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG**

Title of Invention: **Monoclonal Antibodies To Growth And Differentiation Factor 15 (Gdf-15)**

Patent No.: **BN/N/2016/0088**

Date of Grant: **19 June, 2015**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **NIPPON STEEL & SUMITOMO METAL CORPORATION**
VALLOUREC OIL AND GAS FRANCE

Title of Invention: **Threaded Coupling For Steel Piping**

Patent No.: **BN/N/2015/0043**

Date of Grant: **05 February, 2015**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **BIOGENIC CO. LTD.**
NIPPON SUISAN KAISHA, LTD.

Title of Invention: **Method For Producing Astaxanthin**

Patent No.: **RE/R/2018/0001**

Date of Grant: **13 January, 2017**

Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**CRYSTAL LAGOONS (CURACAO) B.V.**
Title of Invention:	**Efficient Filtration Process Of Water In A Tank For Recreational And Ornamental Uses, Where The Filtration Is Performed Over A Small Volume Of Water And Not Over The Totality Of The Water From The Tank**

Patent No.:	**BN/N/2014/0062**
Date of Grant:	**17 January, 2013**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC MANNSMANN OIL & GAS FRANCE**
Title of Invention:	**Threaded Joint For Pipes**

Patent No.:	**BN/N/2015/0098**
Date of Grant:	**22 February, 2014**
Annuity:	**9th Year**
Applicant(s) / Proprietor(s):	**SHODA SHOYU CO., LTD.** **SOY & WORLD INC.**
Title of Invention:	**Process For Manufacturing Soybean Paste, And Soybean Paste**

Patent No.:	**BN/N/2018/0068**
Date of Grant:	**25 January, 2017**
Annuity:	**6th Year**
Applicant(s) / Proprietor(s):	**AMGEN INC.** **AMGEN RESEARCH (MUNICH) GMBH**
Title of Invention:	**Pharmaceutical Composition Comprising Bispecific Antibody Constructs**

Patent No.:	**BN/N/2019/0072**
Date of Grant:	**27 December, 2017**
Annuity:	**5th Year**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**Threaded Joint For Steel Pipes**

Patent No.:	**RE/R/2012/0005**
Date of Grant:	**31 January, 2011**
Annuity:	**12th Year**
Applicant(s) / Proprietor(s):	**SUMITOMO METAL INDUSTRIES LTD.** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Tubular Threaded Joint**

Patent No.:	**RE/R/2014/0009**
Date of Grant:	**31 January, 2013**
Annuity:	**10th Year**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Chemical Compounds**

Patent No.:	**RE/R/2016/0016**
Date of Grant:	**08 January, 2016**
Annuity:	**7h Year**
Applicant(s) / Proprietor(s):	**JANSSEN SCIENCES IRELAND UC**
Title of Invention:	**Indoles As Respiratory Syncytial Virus Antiviral Agents**

Patent No.: RE/R/2016/0033

Date of Grant: 29 December 2015

Annuity: 7th Year

Applicant(s) / Proprietor(s): INCYTE HOLDINGS CORPORATION

Title of Invention: Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1h-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile

---

Patent No.: RE/R/2017/0051

Date of Grant: 13 January, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): AGC INC.
SANTEN PHARMACEUTICAL CO., LTD.

Title of Invention: Method And Composition For Treating Ocular Hypertension And Glaucoma

---

Patent No.: RE/R/2018/0002

Date of Grant: 16 January, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): CYTOKINETICS, INC.

Title of Invention: Certain Amino-Pyridazines, Compositions Thereof, And Methods Of Their Use

---

Patent No.: RE/R/2018/0008

Date of Grant: 15 December, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): SUMITOMO METAL INDUSTRIES, LTD.
VALLOUREC MANNESMANN OIL & GAS FRANCE

Title of Invention: Threaded Connection

Patent No.:	**RP/R/2003/0034**
Date of Grant:	**08 January, 2003**
Annuity:	**20th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Expandable Well Screen**

Patent No.:	**RP/R/2010/0007**
Date of Grant:	**13 January, 2010**
Annuity:	**13th Year**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Method For Production Metering Of Oil Wells**

REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT GRANTED UNDER SECTION 30

Application No.:	**BN/N/2018/0036**
Date of Grant:	**04 December, 2021**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL INDUSTRIES LTD.** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Threaded Connection For Pipe Or Tube And Method Of Producing The Threaded Connection For Pipe Or Tube**

Application No.:	**BN/N/2018/0053**
Date of Grant:	**04 May, 2021**
Applicant(s) / Proprietor(s):	**THE UNIVERSITY OF BRITISH COLUMBIA**
Title of Invention:	**Anti-Fibrogenic Compounds, Method And Uses Therof**

Application No.:	**BN/N/2018/0070**
Date of Grant:	**16 January, 2021**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB** **EOLAS THERAPEUTICS, INC.**
Title of Invention:	**Halo-Substituted Piperidines As Orexin Receptor Modulators**

Application No.:	**BN/N/2018/0078**
Date of Grant:	**16 June, 2021**
Applicant(s) / Proprietor(s):	**SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.**
Title of Invention:	**Chemically-Selective Imager For Imaging Fluid Of A**

Subsurface Formation And Method Of Using Same

Application No.:	**BN/N/2019/0010**
Date of Grant:	**11 November, 2020**
Applicant(s) / Proprietor(s):	**GROW SOLUTIONS TECH LLC**
Title of Invention:	**Track System And Method For Providing A Track For An Industrial Cart**

Application No.:	**BN/N/2019/0020**
Date of Grant:	**27 February, 2020**
Applicant(s) / Proprietor(s):	**2ELMS PTE LTD**
Title of Invention:	**A Lintel**

Application No.:	**BN/N/2019/0035**
Date of Grant:	**23 September, 2021**
Applicant(s) / Proprietor(s):	**CHUGAI SEIYAKU KABUSHIKI KAISHA**
Title of Invention:	**Pyrazolopyridine Derivative Having Glp-1 Receptor Agonist Effect**

Application No.:	**BN/N/2019/0038**
Date of Grant:	**28 September, 2021**
Applicant(s) / Proprietor(s):	**MERCK SHARP & DOHME CORP.**
Title of Invention:	**Chromane, Isochromane And Dihydroisobenzofuran Derivatives As Mglur2-Negative Allosteric Modulators, Compositions, And Their Use**

Application No.:	**BN/N/2019/0051**
Date of Grant:	**07 August, 2019**

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Mechanical Downhole Pressure Maintenance System

---

Application No.: BN/N/2019/0053

Date of Grant: 11 October, 2021

Applicant(s) / Proprietor(s): ARRAY BIOPHARMA INC.

Title of Invention: Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

---

Application No.: BN/N/2019/0055

Date of Grant: 09 October, 2021

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.

Title of Invention: Method For Sealing Cavities In Or Adjacent To A Cured Cement Sheath Surrounding A Well Casing

---

Application No.: BN/N/2019/0092

Date of Grant: 16 January, 2021

Applicant(s) / Proprietor(s): WANG, CHAO KAI
WANG, CHEN LU

Title of Invention: Waterproof And Electricity-Insulating Support Structure For Solar Panels

---

Application No.: BN/N/2020/0001

Date of Grant: 05 January, 2021

Applicant(s) / Proprietor(s): GP NETWORK ASIA PTE. LTD.

Title of Invention: Processing Payments

Application No.: BN/N/2020/0002

Date of Grant: 04 January, 2021

Applicant(s) / Proprietor(s): GP NETWORK ASIA PTE. LTD.

Title of Invention: Processing Payments

Application No.: BN/N/2020/0023

Date of Grant: 06 March, 2021

Applicant(s) / Proprietor(s): INCYTE CORPORATION

Title of Invention: Salts Of Pyrrolotriazine Derivatives Useful As Tam Inhibitors

---

Application No.: BN/N/2020/0033

Date of Grant: 22 February, 2021

Applicant(s) / Proprietor(s): HYDRA SYSTEMS AS

Title of Invention: A System And Method Of Cleaning An Annular Area In A Well

---

Application No.: BN/N/2020/0047

Date of Grant: 09 December, 2021

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Compositions Comprising Streptococcus Pneumoniae Polysaccharide-Protein Conjugates And Methods Of Use Thereof

---

Application No.: BN/N/2020/0056

Date of Grant: 17 July, 2021

Applicant(s) / Proprietor(s): CRYSTAL LAGOONS TECHNOLOGIES, INC.

Title of Invention: A Publicly Accessible Urban Beach Entertainment Complex With A Centerpiece Man-Made Tropical-Style Lagoon And Method For Providing Efficient Utilization Of Limited Use Land

---

Application No.:	**BN/N/2020/0060**
Date of Grant:	**25 November, 2020**
Applicant(s) / Proprietor(s):	**HALLIBURTON ENERGY SERVICES, INC.**
Title of Invention:	**Systems And Methods For Gravel Packing Wells**

Application No.:	**BN/N/2020/0062**
Date of Grant:	**19 May, 2021**
Applicant(s) / Proprietor(s):	**NICOX S.A.**
Title of Invention:	**Process For The Preparation Of A Nitric Oxide Donating Prostaglandin Analogue**

Application No.:	**BN/N/2020/0064**
Date of Grant:	**16 August, 2021**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Arginase Inhibitors And Methods Of Use Thereof**

Application No.:	**BN/N/ 2020/0087**
Date of Grant:	**05 July, 2021**
Applicant(s) / Proprietor(s):	**NIPPON STEEL CORPORATION** **VALLOUREC OIL AND GAS FRANCE**
Title of Invention:	**TUBULAR THREADED CONNECTION**

Application No.:	**BN/N/ 2020/0088**
Date of Grant:	**10 July, 2021**
Applicant(s) / Proprietor(s):	**NIPPON STEEL & SUMITOMO METAL CORPORATION** **VALLOUREC MANNESMANN OIL & GAS FRANCE**
Title of Invention:	**Tubular Threaded Connection For Casing**

Application No.:	**BN/N/2020/0096**
Date of Grant:	**28 August, 2021**
Applicant(s) / Proprietor(s):	**ASTRAZENECA AB**
Title of Invention:	**Tetracyclic Heteroaryl Compounds**

Application No.:	**BN/N/2020/0098**
Date of Grant:	**18 September, 2021**
Applicant(s) / Proprietor(s):	**SMART INSTALLATIONS AS**
Title of Invention:	**Pinning Tool For Pinning A Tubular Structure**

Application No.:	**BN/N/2020/0099**
Date of Grant:	**10 November, 2021**
Applicant(s) / Proprietor(s):	**INCYTE CORPORATION**
Title of Invention:	**Tetrahydro-Imidazo[4,5-C]Pyridine Derivatives As Pd-L1 Immunomodulators**

Application No.:	**BN/N/2021/0001**
Date of Grant:	**29 December, 2021**
Applicant(s) / Proprietor(s):	**NICOX S.A.**
Title of Invention:	**Ophthalmic Compositions Containing A Nitric Oxide Releasing Prostamide**

Application No.:	**BN/N/2021/0031**
Date of Grant:	**09 August, 2021**
Applicant(s) / Proprietor(s):	**CHINA PETROLEUM & CHEMICAL CORPORATION**
Title of Invention:	**Phosphorus-Containing High-Silicon Molecular Sieve, Preparation Method Therefor And Application Thereof**

REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

RECORDAL OF CHANGE OF NAME

(The name in *italic* is the previous proprietor's name)

Application No.: **BN/N/2019/0100**

Applicant(s) / Proprietor(s): **SINGAPORE HEALTH SERVICES PTE LTD of 31 Third Hospital Avenue #03-03 Bowyer Block C Singapore 168753**

SINGAPORE HEALTH SERVICES PTE LTD **of The Academia 20 College Road, Discovery Tower Level 6 Singapore 169856**

Title of Invention: **COMPOSITION AND METHOD FOR PREVENTING OR DELAYING ONSET OF MYOPIA COMPRISING ATROPINE**

Agent and/ or Address for Service :

Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

---

Application No.: **BN/N/2019/0002**

Applicant(s) / Proprietor(s): **ROMAIN BORDES of Chalmers Tekniska Hogskola AB Kemivagen 4, 412 96 Goteborg, France [FR]**

ROMAIN BORDES **of Chalmers Tekniska Hogskola AB Kemivagen 4, 412 96 Goteborg, Sweden [SE]**

Title of Invention: **PHARMACEUTICAL COMPOSITIONS**

Agent and/ or Address for Service :

Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

---

Application No.: **BN/N/2020/0020**

Applicant(s) / Proprietor(s):	**CHINOOK THERAPEUTICS, INC. of 740 Heinz Avenue, Berkeley, California 94710, United States Of America** ***ADURO BIOTECH, INC.* of 740 Heinz Avenue, Berkeley, California 94710, United States Of America**
Title of Invention:	**PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF**

Agent and/ or Address for Service :

Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

---